U.S. patent application number 16/656453 was filed with the patent office on 2020-02-13 for compositions and methods of use.
This patent application is currently assigned to Kirit Shah. The applicant listed for this patent is Kirit Shah. Invention is credited to Bharti Ajit, Vipul C. Chitalia, Xiong Fu, Gamini S. Jayatilake, Daniel Prabakaran.
Application Number | 20200046786 16/656453 |
Document ID | / |
Family ID | 42340288 |
Filed Date | 2020-02-13 |
![](/patent/app/20200046786/US20200046786A1-20200213-C00001.png)
![](/patent/app/20200046786/US20200046786A1-20200213-C00002.png)
![](/patent/app/20200046786/US20200046786A1-20200213-C00003.png)
![](/patent/app/20200046786/US20200046786A1-20200213-C00004.png)
![](/patent/app/20200046786/US20200046786A1-20200213-C00005.png)
![](/patent/app/20200046786/US20200046786A1-20200213-C00006.png)
![](/patent/app/20200046786/US20200046786A1-20200213-C00007.png)
![](/patent/app/20200046786/US20200046786A1-20200213-D00001.png)
![](/patent/app/20200046786/US20200046786A1-20200213-D00002.png)
![](/patent/app/20200046786/US20200046786A1-20200213-D00003.png)
![](/patent/app/20200046786/US20200046786A1-20200213-D00004.png)
View All Diagrams
United States Patent
Application |
20200046786 |
Kind Code |
A1 |
Chitalia; Vipul C. ; et
al. |
February 13, 2020 |
COMPOSITIONS AND METHODS OF USE
Abstract
This invention relates to the use of plant extracts,
compositions thereof, and compounds isolated from plant extracts or
obtained from synthetic means thereof, for the treatment of
diseases, disorders or symptoms thereof (e.g., proliferation
disorders, cancer).
Inventors: |
Chitalia; Vipul C.;
(Cambridge, MA) ; Prabakaran; Daniel; (Wayland,
MA) ; Ajit; Bharti; (West Roxbury, MA) ;
Jayatilake; Gamini S.; (Broomfield, CO) ; Fu;
Xiong; (Superior, CO) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Shah; Kirit |
|
|
US |
|
|
Assignee: |
Shah; Kirit
Portland
OR
|
Family ID: |
42340288 |
Appl. No.: |
16/656453 |
Filed: |
October 17, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12687769 |
Jan 14, 2010 |
10478464 |
|
|
16656453 |
|
|
|
|
61205144 |
Jan 14, 2009 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 35/00 20180101;
A61P 11/00 20180101; A61P 35/02 20180101; A61K 31/20 20130101; A61P
1/16 20180101; A61K 36/11 20130101; A61K 45/06 20130101; A61K 31/20
20130101; A61K 2300/00 20130101; A61K 36/11 20130101; A61K 2300/00
20130101 |
International
Class: |
A61K 36/11 20060101
A61K036/11; A61K 45/06 20060101 A61K045/06; A61K 31/20 20060101
A61K031/20 |
Claims
1. A method of treating cancer in a subject comprising
administration of a composition comprising a a compound that occurs
in an extract from Lycopodium clavatum to the subject.
2. The method of claim 1, wherein the composition comprises a
BCP-21 extract fraction.
3. The method of claim 1, wherein the composition comprises an
isolated compound from a BCP-21 extract fraction.
4. The method of claim 1 wherein the composition comprises isolated
8-hydroxyhexadecanoic acid.
5. The method of claim 1 wherein the composition comprises
synthetic 8-hydroxyhexadecanoic acid.
6. The method of claim 1, wherein the composition comprises
S-enantiomer of 8-hydroxy-palmitic acid.
7. The method of claim 1 comprising the concurrent administration
of an additional therapeutic agent.
8. The method of claim 7 wherein the additional therapeutic agent
is an anticancer agent.
9. The method of claim 1, wherein the cancer is a cancer mediated
by caspase-3.
10. The method of claim 1, wherein the cancer is
hepatocellular.
11. The method of claim 1, wherein the cancer is a liver
cancer.
12. The method of claim 1, wherein the cancer is a lung cancer.
13. The method of claim 12, wherein the lung cancer is a non-small
cell lung cancer.
14. The method of claim 12, wherein the lung cancer relates to
HOP-92 cancer cells.
15. The method of claim 1, wherein the cancer is a leukemia.
16. A kit comprising a compound that occurs in an extract of
Lycopodium clavatum.
17. The kit of claim 16, wherein the compound is
8-hydroxyhexadecanoic acid.
18. The kit of claim 16, further comprising instructions to
administer the compound to a subject identified as in need of a
cancer therapy.
19. The kit of claim 16, further comprising instructions to
administer an additional anticancer agent.
20. A pharmaceutical composition comprising 8-hydroxyhexadecanoic
acid and a pharmaceutically acceptable carrier.
21. A composition comprising 8-hydroxyhexadecanoic acid for use in
the treatment of cancer in a subject.
Description
CROSS-REFERENCED TO RELATED APPLICATIONS
[0001] This present application is a divisional of U.S. application
Ser. No. 12/687,769, filed Jan. 14, 2010, entitled "Compositions
and Methods of Use," currently granted, which claims the benefit of
and priority to U.S. Provisional Patent Application No. 61/205,144,
filed on Jan. 14, 2009, entitled "Compositions and Methods of Use,"
the contents of all of which are hereby incorporated by reference
in their entirety.
TECHNICAL FIELD OF THE INVENTION
[0002] This invention relates to plant extract compositions,
isolated active agents, and methods of use for the treatment of
cancer.
[0003] The identification of new extracts and compounds for
therapeutic use is of continuing biomedical importance and natural
products continue to garner attention for this endeavor.
Proliferation disorders continue to provide challenges to the
health of humans and animals and treatment regimens for such
disorders remain as an unmet need across a broad spectrum. Because
of the variation of mechanisms, signaling processes, and targets
involved in proliferation disorders, identification of new and more
efficacious compositions, compounds and methods of treatment is of
great interest to the medical community as well as the public at
large.
[0004] Lycopodium clavatum, also known as Wolfs Foot and Club Moss
Lycopodiaceae, belongs to genus Lycopodium and family
Lycopodiaceae. It derives its name as wolf s foot as the branch
tips resemble a wolf s paws (lukos means wolf and podos means
foot). The plant is ubiquitiously found in subtropical and tropical
forests in the world. The sporophyte produces spores within
sporangia after meiosis. In Lycopodium the sporangia are clustered
into cone-like strobili in which each sporangium is protected by a
leaf-like sporophyll. The extract from the spores of the plant was
fractionated to yield isolated extracts and compounds in the search
for new and interesting compositions having novel therapeutic
activity.
SUMMARY OF THE INVENTION
[0005] This invention relates to the method of using a plant
extract herein to treat a proliferation disorder in a subject. One
aspect of this invention the method of using an isolated compound
from a plant extract herein to treat a proliferation disorder in a
subject. In one embodiment, the proliferation disorder is a cancer.
Certain embodiments provide that the cancer is a leukemia, lung
cancer, liver cancer, or colon cancer. In one embodiment, the
cancer is a non-small cell lung cancer. In another embodiment, the
cancer is a liver cancer.
[0006] In one embodiment, the compound is 8-hydroxy-palmitic acid
("8-HHA"), or a salt, prodrug, prodrug salt, solvate, hydrate, and
polymorph thereof. In another embodiment, the compound used in
accordance with the methods of this invention is a racemic mixture
of R- and S-enantiomers of 8-hydroxy-palmitic acid. In one
embodiment, the compound is the S-enantiomer of 8-hydroxy-palmitic
acid ("(S)-8-HHA"). In another embodiment, the compound is the
R-enantiomer of 8-hydroxy-palmitic acid ("(R)-8-HHA").
[0007] Another aspect of this invention is a composition comprising
a plant extract herein (e.g., extract of Lycopodium clavatum).
Another aspect is a composition comprising an isolated compound
from a plant extract herein. Another aspect is a composition
comprising an isolated compound from a plant extract herein having
one or more substituent(s).
[0008] Another aspect is a compound (or combinations of compounds)
delineated herein (or methods using the compounds/combinations
delineated herein) wherein the compound or compound combinations
are demonstrated to possess anticancer activity in a subject (e.g.,
animal model, mouse, rat, rabbit, primate, human). Examples herein
are instructive for representative methods to determine such
effect.
[0009] In one embodiment, the compound (or combinations of
compounds) delineated herein is obtained from a procedure
comprising extraction from a plant. In certain embodiments, the
procedure for use in obtaining the compound (or combinations of
compounds) further includes any of isolation, evaporation, and
partitioning steps of the plant extracts.
[0010] In another embodiment, the compound (or combinations of
compounds) delineated herein is obtained from a synthetic
means.
[0011] Another aspect of this invention is a pharmaceutical
composition comprising a plant extract herein (e.g., BCP-21
extracts, any of BCP-21 extract fractions in Tables 1 or 2) or a
compound (e.g., 8-hydroxyhexadecanoic acid, any of BCP compounds
1-10 herein) that occurs in a plant extract herein (e.g., BCP-21
extracts, any of BCP-21 extract fractions in Tables 1 or 2). In one
embodiment, the pharmaceutical composition comprises a racemic
mixture of 8-HHA, or a salt, prodrug, prodrug salt, solvate,
hydrate, and polymorph thereof. In one embodiment, the
pharmaceutical composition comprises the S-enantiomer of
8-hydroxy-palmitic acid ("(S)-8-HHA") in a substantial enantiomeric
purity. In another embodiment, the pharmaceutical composition
comprises the R-enantiomer of 8-hydroxy-palmitic acid ("(R)-8-HHA")
in a substantial enantiomeric purity.
[0012] In another aspect, such compositions can be included in a
kit.
[0013] The above compositions (and method of treatment delineated
herein) may be further combined with appropriate chemo- and
biotherapeutic agents. Examples of such agents include but are not
limited to Aldesleukin, Alemtuzumab, Alitretinoin, Altretamine,
Aminolevulinic acid, Anagrelide, Anastrozole, Arsenic trioxide,
Asparaginase, Bacille Calmette-Guerin (BCG), Betamethasone,
Bexarotene, Bicalutamide, Bleomycin, Busulfan, Capecitabine,
Carboplatin, Carmustine, Chlorambucil, Chromic phosphate P-32,
Cisplatin, Cladribine, Conjugated estrogens, Cortisone,
Cyclophosphamide, Cytarabine liposome, Cytarabine, ara-,
Dacarbazine, Dactinomycin, actinomycin D, Daunorubicin,
Daunorubicin citrate liposome, Denileukin diftitox, Dexamethasone,
Diclofenac, Docetaxel, Doxorubicin, Doxorubicin liposome,
Epirubicin, Esterified estrogens, Estradiol, Estradiol valerate,
Estramustine, Estrone, Ethinyl estradiol, Etoposide, Etoposide
phosphate, Exemestane, Floxuridine, Fludarabine phosphate,
Fluorouracil, Fluorouracil, Fluorouracil, Fluoxymesterone,
Flutamide, Gemcitabine, Gemtuzumab ozogamicin, Goserelin acetate,
Granisetron, Hydrocortisone, Hydroxyprogesterone, Hydroxyurea,
Ibritumomab tiuxetan, Idarubicin, Ifosfamide, Imatinib mesylate,
Interferon alfa-2a, Interferon alfa-2b, Irinotecan, Letrozole,
Leuprolide acetate, Levothyroxine, Lomustine, Mechlorethamine,
Medroxyprogesterone, Medroxyprogesterone, Megestrol acetate,
Melphalan, Mercaptopurine, Methotrexate sodium, Methoxsalen,
Methylprednisolone, Methyltestosterone, Metyrosine, Mitomycin,
mitomycin-c, Mitotane, Mitoxantrone, Nandrolone phenpropionate,
Nilutamide, Octreotide acetate, Oprelvekin, Oxymetholone,
Pegaspargase, Pentostatin, Plicamycin, Polifeprosan 20/carmustine,
Porfimer sodium, Prednisolone, Prednisone, Procarbazine,
Progesterone, Rituximab, Samarium-153 lexidronam pentasodium,
Sodium iodide I-131, Sodium phosphate P-32, Streptozocin,
Strontium-89 chloride, Talc, Tamoxifen citrate, Temozolomide,
Teniposide, Testolactone, Testosterone enanthate, Thioguanine,
Thiotepa, Topotecan, Toremifene citrate, Trastuzumab, Tretinoin,
Triamcinolone, Triptorelin pamoate, Valrubicin, Vinblastine,
Vincristine and Vinorelbine.
[0014] In yet another aspect, the invention provides the use of a
compound of any of the formulae herein, alone or together with one
or more additional therapeutic agents in the manufacture of a
medicament, either as a single composition or as separate dosage
forms, for treatment or prevention in a subject of a disease,
disorder or symptom set forth herein. Another aspect of the
invention is a compound of the formulae herein (isolated natural or
synthetic) for use in the treatment or prevention in a subject of a
disease, disorder or symptom thereof delineated herein.
DESCRIPTION OF THE FIGURES
[0015] FIG. 1-FIG. 3 are NMR spectra of a compound isolated from
BCP-21 extract.
[0016] FIG. 4-FIG. 5 are MS spectra of a compound isolated from
BCP-21 extract.
[0017] FIG. 6 shows that BCP-21 induces apoptosis of HeLa cells in
a dose-dependent manner.
[0018] FIG. 7 is a western blotting result showing that the extract
of Lycopodium clavatum induces PARP cleavage in a time-dependent
manner.
[0019] FIG. 8 shows that (S)-8-HHA inhibited HOP-92 lung cancer
cell line survival in a dose dependent manner.
[0020] FIG. 9 shows that 100 .mu.M of 8-HHA (the racemic mixture,
S- or R-enantiomer) resulted in reduces survival of PCL5, Hep3B and
SNU liver cancer cell lines using colorimetric MTT assay.
[0021] FIG. 10 demonstrates that (S)-8-HHA inhibited PLC-5 liver
cancer cell line survival in a dose dependent manner.
[0022] FIG. 11 shows that 100 .mu.M of (S)-8-HHA resulted in the
PARP cleavage in SNU and PCL5 liver cancer cell lines.
[0023] FIG. 12 demonstrates that a treatment of (S)-8-HHA resulted
in a substantial reduction in FAS receptor levels compared to the
control.
[0024] FIG. 13 depicts that 8-HHA decreases tumor growth in PLC5
liver cancer cells in liver xenograft mouse model.
[0025] FIG. 14 depicts anti-tumor efficacy of 8-HHA in HOP92 lung
cancer cells in xenograft mouse model.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0026] The terms "ameliorate" and "treat" are used interchangeably
and both mean decrease, suppress, attenuate, diminish, arrest, or
stabilize the development or progression of a disease (e.g., a
disease or disorder delineated herein).
[0027] By "disease" is meant any condition or disorder that damages
or interferes with the normal function of a cell, tissue, or
organ.
[0028] By "marker" is meant any alteration that is associated with
a disease or disorder. For example, any protein or polynucleotide
having an alteration in expression level or activity that is
associated with a disease or disorder.
[0029] The term "cancers" generally refers to a class of diseases
in which a group of cells display uncontrolled growth (division
beyond the normal limits), invasion (intrusion on and destruction
of adjacent tissues) and sometimes metastasis (spread to other
locations in body). Examples of cancers include, but are not
limited to, leukemia, lung cancers, liver cancers, colon cancers,
melanoma, breast cancers, CNS cancers, ovarian cancers, renal
cancers, and prostate cancers. In this disclosure, "comprises,"
"comprising," "containing" and "having" and the like can have the
meaning ascribed to them in U.S. Patent law and can mean
"includes," "including," and the like; "consisting essentially of
or "consists essentially" likewise has the meaning ascribed in U.S.
Patent law and the term is open-ended, allowing for the presence of
more than that which is recited so long as basic or novel
characteristics of that which is recited is not changed by the
presence of more than that which is recited, but excludes prior art
embodiments.
[0030] The compounds herein can also be utilized in compound forms
including salts, prodrugs, and prodrug salts, solvates, hydrates,
and polymorphs of a compound of a formulae herein.
[0031] A salt of a compound of this invention is formed between an
acid and a basic group of the compound, such as an amino functional
group, or a base and an acidic group of the compound, such as a
carboxyl functional group. According to another preferred
embodiment, the compound is a pharmaceutically acceptable acid
addition salt.
[0032] As used herein and unless otherwise indicated, the term
"prodrug" means a derivative of a compound that can hydrolyze,
oxidize, or otherwise react under biological conditions (in vitro
or in vivo) to provide a compound of this invention. Prodrugs may
only become active upon such reaction under biological conditions,
or they may have activity in their unreacted forms. Examples of
prodrugs contemplated in this invention include, but are not
limited to, analogs or derivatives of compounds of any one of the
formulae disclosed herein that comprise biohydrolyzable moieties
such as amides, esters, carbamates, carbonates, and phosphate
analogues. Prodrugs can typically be prepared using well-known
methods, such as those described by Burger's Medicinal Chemistry
and Drug Discovery (1995) 172-178, 949-982 (Manfred E. Wolff ed.,
5th ed); see also Goodman and Gilman's, The Pharmacological basis
of Therapeutics, 8th ed., McGraw-Hill, Int. Ed. 1992,
"Biotransformation of Drugs".
[0033] As used herein and unless otherwise indicated, the term
"biohydrolyzable moiety" means a functional group (e.g., amide,
ester, carbamate, carbonate, or phosphate) analogue, that either:
1) does not destroy the biological activity of the compound and
confers upon that compound advantageous properties in vivo, such as
uptake, duration of action, or onset of action; or 2) is itself
biologically inactive but is converted in vivo to a biologically
active compound.
[0034] A prodrug salt is a compound formed between an acid and a
basic group of the prodrug, such as an amino functional group, or a
base and an acidic group of the prodrug, such as a carboxyl
functional group. In a one embodiment, the prodrug salt is a
pharmaceutically acceptable salt.
[0035] Particularly favored prodrugs and prodrug salts are those
that increase the bioavailability of the compounds of this
invention when such compounds are administered to a mammal (e.g.,
by allowing an orally administered compound to be more readily
absorbed into the blood) or which enhance delivery of the parent
compound to a biological compartment (e.g., the brain or central
nervous system) relative to the parent species. Preferred prodrugs
include derivatives where a group that enhances aqueous solubility
or active transport through the gut membrane is appended to the
structure of formulae described herein. See, e.g., Alexander, J. et
al. Journal of Medicinal Chemistry 1988, 31, 318-322; Bundgaard, H.
Design of Prodrugs; Elsevier: Amsterdam, 1985; pp 1-92; Bundgaard,
H.; Nielsen, N. M. Journal of Medicinal Chemistry 1987, 30,
451-454; Bundgaard, H. A Textbook of Drug Design and Development;
Harwood Academic Publ.: Switzerland, 1991; pp 113-191; Digenis, G.
A. et al. Handbook of Experimental Pharmacology 1975, 28, 86-112;
Friis, G. J.; Bundgaard, H. A Textbook of Drug Design and
Development; 2 ed.; Overseas Publ.: Amsterdam, 1996; pp 351-385;
Pitman, I. H. Medicinal Research Reviews 1981, 1, 189-214.
[0036] The term "pharmaceutically acceptable," as used herein,
refers to a component that is, within the scope of sound medical
judgment, suitable for use in contact with the tissues of humans
and other mammals without undue toxicity, irritation, allergic
response and the like, and are commensurate with a reasonable
benefit/risk ratio. A "pharmaceutically acceptable salt" means any
non-toxic salt that, upon administration to a recipient, is capable
of providing, either directly or indirectly, a compound or a
prodrug of a compound of this invention.
[0037] Acids commonly employed to form pharmaceutically acceptable
salts include inorganic acids such as hydrogen bisulfide,
hydrochloric, hydrobromic, hydroiodic, sulfuric and phosphoric
acid, as well as organic acids such as para-toluenesulfonic,
salicylic, tartaric, bitartaric, ascorbic, maleic, besylic,
fumaric, gluconic, glucuronic, formic, glutamic, methanesulfonic,
ethanesulfonic, benzenesulfonic, lactic, oxalic,
para-bromophenylsulfonic, carbonic, succinic, citric, benzoic and
acetic acid, and related inorganic and organic acids. Such
pharmaceutically acceptable salts thus include sulfate,
pyrosulfate, bisulfate, sulfite, bisulfate, phosphate,
monohydrogenphosphate, dihydrogenphosphate, metaphosphate,
pyrophosphate, chloride, bromide, iodide, acetate, propionate,
decanoate, caprylate, acrylate, formate, isobutyrate, caprate,
heptanoate, propiolate, oxalate, malonate, succinate, suberate,
sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate,
benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate,
hydroxybenzoate, methoxybenzoate, phthalate, terephathalate,
sulfonate, xylenesulfonate, phenylacetate, phenylpropionate,
phenylbutyrate, citrate, lactate, (3-hydroxybutyrate, glycolate,
maleate, tartrate, methanesulfonate, propanesulfonate,
naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the
like salts. Preferred pharmaceutically acceptable acid addition
salts include those formed with mineral acids such as hydrochloric
acid and hydrobromic acid, and especially those formed with organic
acids such as maleic acid.
[0038] Suitable bases for forming pharmaceutically acceptable salts
with acidic functional groups of prodrugs of this invention
include, but are not limited to, hydroxides of alkali metals such
as sodium, potassium, and lithium; hydroxides of alkaline earth
metal such as calcium and magnesium; hydroxides of other metals,
such as aluminum and zinc; ammonia, and organic amines, such as
unsubstituted or hydroxy-substituted mono-, di-, or trialkylamines;
dicyclohexylamine; tributyl amine; pyridine; N-methyl,N-ethylamine;
diethylamine; triethylamine; mono-, bis-, or tris-(2-hydroxy-lower
alkyl amines), such as mono-, bis-, or tris-(2-hydroxyethyl)amine,
2-hydroxy-tert-butylamine, or tris-(hydroxymethyl)methylamine, N,
N,-di-lower alkyl-N-(hydroxy lower alkyl)-amines, such as
N,N-dimethyl-N-(2-hydroxyethyl)amine, or tri-(2-hydroxyethyl)amine;
N-methyl-D-glucamine; and amino acids such as arginine, lysine, and
the like.
[0039] As used herein, the term "hydrate" means a compound which
further includes a stoichiometric or non-stoichiometric amount of
water bound by non-covalent intermolecular forces.
[0040] The terms "isolated," "purified," or "biologically pure"
refer to material that is substantially or essentially free from
components that normally accompany it as found in its native state.
Purity and homogeneity are typically determined using analytical
chemistry techniques such as polyacrylamide gel electrophoresis or
high performance liquid chromatography. Particularly, in
embodiments the compound is at least 85% pure, more preferably at
least 90% pure, more preferably at least 95% pure, and most
preferably at least 99% pure.
[0041] As used herein, the term "solvate" means a compound which
further includes a stoichiometric or non-stoichiometric amount of
solvent such as water, acetone, ethanol, methanol, dichloromethane,
2-propanol, or the like, bound by non-covalent intermolecular
forces.
[0042] As used herein, the term "polymorph" means solid crystalline
forms of a compound or complex thereof which may be characterized
by physical means such as, for instance, X-ray powder diffraction
patterns or infrared spectroscopy. Different polymorphs of the same
compound can exhibit different physical, chemical and/or
spectroscopic properties. Different physical properties include,
but are not limited to stability (e.g., to heat, light or
moisture), compressibility and density (important in formulation
and product manufacturing), hygroscopicity, solubility, and
dissolution rates (which can affect bioavailability). Differences
in stability can result from changes in chemical reactivity (e.g.,
differential oxidation, such that a dosage form discolors more
rapidly when comprised of one polymorph than when comprised of
another polymorph) or mechanical characteristics (e.g., tablets
crumble on storage as a kinetically favored polymorph converts to
thermodynamically more stable polymorph) or both (e.g., tablets of
one polymorph are more susceptible to breakdown at high humidity).
Different physical properties of polymorphs can affect their
processing. For example, one polymorph might be more likely to form
solvates or might be more difficult to filter or wash free of
impurities than another due to, for example, the shape or size
distribution of particles of it.
[0043] The term "substantially free of other stereoisomers" as used
herein means less than 25% of other stereoisomers, preferably less
than 10% of other stereoisomers, more preferably less than 5% of
other stereoisomers and most preferably less than 2% of other
stereoisomers, or less than "X"% of other stereoisomers (wherein X
is a number between 0 and 100, inclusive) are present. Methods of
obtaining or synthesizing diastereomers are well known in the art
and may be applied as practicable to final compounds or to starting
material or intermediates. Other embodiments are those wherein the
compound is an isolated compound. The term "at least X %
enantiomerically enriched" as used herein means that at least X %
of the compound is a single enantiomeric form, wherein X is a
number between 0 and 100, inclusive.
[0044] The term "stable compounds", as used herein, refers to
compounds which possess stability sufficient to allow manufacture
and which maintain the integrity of the compound for a sufficient
period of time to be useful for the purposes detailed herein (e.g.,
formulation into therapeutic products, intermediates for use in
production of therapeutic compounds, isolatable or storable
intermediate compounds, treating a disease or condition responsive
to therapeutic agents).
[0045] "Stereoisomer" refers to both enantiomers and
diastereomers.
[0046] As used herein, the term "halo" or "halogen" refers to any
radical of fluorine, chlorine, bromine or iodine.
[0047] The terms "alk" or "alkyl" refer to straight or branched
chain hydrocarbon groups having 1 to 12 carbon atoms, preferably 1
to 8 carbon atoms. The expression "lower alkyl" refers to alkyl
groups of 1 to 4 carbon atoms (inclusive). The term "arylalkyl"
refers to a moiety in which an alkyl hydrogen atom is replaced by
an aryl group. The term "alkenyl" refers to straight or branched
chain hydrocarbon groups of 2 to 10, preferably 2 to 4, carbon
atoms having at least one double bond. Where an alkenyl group is
bonded to a nitrogen atom, it is preferred that such group not be
bonded directly through a carbon bearing a double bond.
[0048] The term "alkoxy" refers to an --O-alkyl radical. The term
"alkylenedioxo" refers to a divalent species of the structure
--O--R--O--, in which R represents an alkylene.
[0049] The term "alkynyl" refers to straight or branched chain
hydrocarbon groups of 2 to 10, preferably 2 to 4, carbon atoms
having at least one triple bond. Where an alkynyl group is bonded
to a nitrogen atom, it is preferred that such group not be bonded
directly through a carbon bearing a triple bond.
[0050] The term "alkylene" refers to a divalent straight chain
bridge of 1 to 5 carbon atoms connected by single bonds (e.g.,
--(CH.sub.2).sub.x--, wherein x is 1 to 5), which may be
substituted with 1 to 3 lower alkyl groups.
[0051] The term "alkenylene" refers to a straight chain bridge of 2
to 5 carbon atoms having one or two double bonds that is connected
by single bonds and may be substituted with 1 to 3 lower alkyl
groups. Exemplary alkenylene groups are --CH.dbd.CH--CH.dbd.CH--,
--CH.sub.2--CH.dbd.CH--, --CH.sub.2--CH.dbd.CH--CH.sub.2--,
--C(CH.sub.3).sub.2CH.dbd.CH-- and
--CH(C.sub.2H.sub.5)--CH.dbd.CH--.
[0052] The term "alkynylene" refers to a straight chain bridge of 2
to 5 carbon atoms that has a triple bond therein, is connected by
single bonds, and may be substituted with 1 to 3 lower alkyl
groups. Exemplary alkynylene groups are --C.ident.C--,
--CH.sub.2--C.ident.C--, --CH(CH.sub.3)--C.ident.C-- and
--C.ident.C--CH(C.sub.2H.sub.5)CH.sub.2--.
[0053] The terms "cycloalkyl" and "cycloalkenyl" as employed herein
includes saturated and partially unsaturated cyclic, respectively,
hydrocarbon groups having 3 to 12 carbons, preferably 3 to 8
carbons, and more preferably 3 to 6 carbons. The terms "Ar" or
"aryl" refer to aromatic cyclic groups (for example 6 membered
monocyclic, 10 membered bicyclic or 14 membered tricyclic ring
systems) which contain 6 to 14 carbon atoms. Exemplary aryl groups
include phenyl, naphthyl, biphenyl and anthracene.
[0054] Heteroaryl" refers to a monocyclic or fused ring (i.e.,
rings which share an adjacent pair of atoms) group of 5 to 12 ring
atoms containing one, two, three or four ring heteroatoms selected
from N, O, or S, the remaining ring atoms being C, and, in
addition, having a completely conjugated pi-electron system,
wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a
substituent. Examples, without limitation, of heteroaryl groups are
pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole,
pyridine, pyrimidine, quinoline, quinazoline, isoquinoline, purine
and carbazole.
[0055] The terms "heterocycle", "heterocyclic" or "heterocyclo"
refer to fully saturated or partially unsaturated cyclic groups,
for example, 3 to 7 membered monocyclic, 7 to 12 membered bicyclic,
or 10 to 15 membered tricyclic ring systems, which have at least
one heteroatom in at least one ring, wherein 0, 1, 2 or 3 atoms of
each ring may be substituted by a substituent. Each ring of the
heterocyclic group containing a heteroatom may have 1, 2, 3 or 4
heteroatoms selected from nitrogen atoms, oxygen atoms and/or
sulfur atoms, where the nitrogen and sulfur heteroatoms may
optionally be oxidized and the nitrogen heteroatoms may optionally
be quaternized. The heterocyclic group may be attached at any
heteroatom or carbon atom of the ring or ring system.
[0056] The term "substituents" refers to a group "substituted" on
any functional group delineated herein, e.g., alkyl, alkenyl,
alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, or
heteroaryl group at any atom of that group. In aspects, functional
group delineated herein, e.g., alkyl, alkenyl, alkynyl, cycloalkyl,
cycloalkenyl, aryl, heterocyclyl, or heteroaryl, can be substituted
with a substituent (e.g., those listed below). Suitable
substituents include, without limitation halogen, CN, NO.sub.2,
OR.sup.15, SR.sup.15, S(O).sub.2OR.sup.15, NR.sup.15R.sup.16,
C.sub.1,-C.sub.2 perfluoroalkyl, C,-C.sub.2 perfluoroalkoxy,
1,2-methylenedioxy, C(O)OR.sup.15, C(O)NR.sup.15R.sup.16,
OC(O)NR.sup.15R.sup.16, NR.sup.15C(O)NR.sup.15R.sup.16,
C(NR.sup.16)NR.sup.15R.sup.16,
NR.sup.15C(NR.sup.16)NR.sup.15R.sup.16,
S(O).sub.2NR.sup.15R.sup.16, R.sup.17, C(O)R.sup.17,
NR.sup.15C(O)R.sup.17, S(O)R.sup.17, S(O).sub.2R.sup.17, R.sup.16,
oxo, C(O)R.sup.16, C(O)(CH.sub.2)nOH, (CH.sub.2)nOR'.sup.5,
(CH.sub.2)nC(O)NR.sup.15R.sup.16, NR.sup.15S(O).sub.2R.sup.17,
where n is independently 0-6 inclusive. Each R.sup.15 is
independently hydrogen, C.sub.1,-C.sub.4 alkyl or C.sub.3-C.sub.6
cycloalkyl. Each R.sup.16 is independently hydrogen, alkenyl,
alkynyl, C.sub.3-C.sub.6 cycloalkyl, aryl, heterocyclyl,
heteroaryl, C.sub.1,-C.sub.4 alkyl or C.sub.1,-C.sub.4 alkyl
substituted with C.sub.3-C.sub.6 cycloalkyl, aryl, heterocyclyl or
heteroaryl. Each R.sup.17 is independently C.sub.3-C.sub.6
cycloalkyl, aryl, heterocyclyl, heteroaryl, C.sub.1,-C.sub.4 alkyl
or C.sub.1,-C.sub.4 alkyl substituted with C.sub.3-C.sub.6
cycloalkyl, aryl, heterocyclyl or heteroaryl. Each C.sub.3-C.sub.6
cycloalkyl, aryl, heterocyclyl, heteroaryl and C.sub.1,-C.sub.4
alkyl in each R.sup.15, R.sup.16 and R.sup.17 can optionally be
substituted with halogen, CN, C.sub.1,-C.sub.4 alkyl, OH,
C.sub.1,-C.sub.4 alkoxy, NH.sub.2, C.sub.1,-C.sub.4 alkylamino,
dialkylamino, perfluoroalkyl, perfluoroalkoxy, or
1,2-methylenedioxy.
[0057] The term "oxo" refers to an oxygen atom, which forms a
carbonyl when attached to carbon, an N-oxide when attached to
nitrogen, and a sulfoxide or sulfone when attached to sulfur.
[0058] The term "acyl" refers to an alkylcarbonyl,
cycloalkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl, or
heteroarylcarbonyl substituent, any of which may be further
substituted by substituents.
[0059] The recitation of a listing of chemical groups in any
definition of a variable herein includes definitions of that
variable as any single group or combination of listed groups. The
recitation of an embodiment for a variable herein includes that
embodiment as any single embodiment or in combination with any
other embodiments or portions thereof.
[0060] The compounds of this invention may contain one or more
asymmetric centers and thus occur as racemates and racemic
mixtures, single enantiomers, individual diastereomers and
diastereomeric mixtures. All such isomeric forms of these compounds
are expressly included in the present invention. The compounds of
this invention may also be represented in multiple tautomeric
forms, in such instances, the invention expressly includes all
tautomeric forms of the compounds described herein. All such
isomeric forms of such compounds are expressly included in the
present invention. All crystal forms of the compounds described
herein are expressly included in the present invention.
[0061] Other approaches to synthesizing compounds of the formulae
herein can readily be adapted from references cited herein.
Variations of these procedures and their optimization are within
the skill of the ordinary practitioner.
[0062] The specific approaches and compounds shown above are not
intended to be limiting. The chemical structures in the schemes
herein depict variables that are hereby defined commensurately with
chemical group definitions (moieties, atoms, etc.) of the
corresponding position in the compound formulae herein, whether
identified by the same variable name (e.g., R', R.sup.2, R, R', X,
etc.) or not. The suitability of a chemical group in a compound
structure for use in synthesis of another compound structure is
within the knowledge of one of ordinary skill in the art.
Additional methods of synthesizing compounds herein and their
synthetic precursors, including those within routes not explicitly
shown in schemes herein, are within the means of chemists of
ordinary skill in the art. Methods for optimizing reaction
conditions, if necessary minimizing competing by-products, are
known in the art. The methods described herein may also
additionally include steps, either before or after the steps
described specifically herein, to add or remove suitable protecting
groups in order to ultimately allow synthesis of the compounds
herein. In addition, various synthetic steps may be performed in an
alternate sequence or order to give the desired compounds.
Synthetic chemistry transformations and protecting group
methodologies (protection and deprotection) useful in synthesizing
the applicable compounds are known in the art and include, for
example, those described in R. Larock, Comprehensive Organic
Transformations, VCH Publishers (1989); T. W. Greene and P.G.M.
Wuts, Protective Groups in Organic Synthesis, 3.sup.rd Ed., John
Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser and Fieser's
Reagents for Organic Synthesis, John Wiley and Sons (1994); and L.
Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John
Wiley and Sons (1995) and subsequent editions thereof.
[0063] The synthetic methods described herein may also additionally
include steps, either before or after any of the steps described in
any scheme, to add or remove suitable protecting groups in order to
ultimately allow synthesis of the compound of the formulae
described herein. The methods delineated herein contemplate
converting compounds of one formula to compounds of another
formula. The process of converting refers to one or more chemical
transformations, which can be performed in situ, or with isolation
of intermediate compounds. The transformations can include reacting
the starting compounds or intermediates with additional reagents
using techniques and protocols known in the art, including those in
the references cited herein. Intermediates can be used with or
without purification (e.g., filtration, distillation, sublimation,
crystallization, trituration, solid phase extraction, and
chromatography).
[0064] Combinations of substituents and variables envisioned by
this invention are only those that result in the formation of
stable compounds.
[0065] The invention also provides compositions comprising an
effective amount of a compounds herein, or a pharmaceutically
acceptable salt, solvate, hydrate, polymorph or prodrug, if
applicable, of said compound; and an acceptable carrier.
Preferably, a composition of this invention is formulated for
pharmaceutical use ("a pharmaceutical composition"), wherein the
carrier is a pharmaceutically acceptable carrier. The carrier(s)
must be "acceptable" in the sense of being compatible with the
other ingredients of the formulation and, in the case of a
pharmaceutically acceptable carrier, not deleterious to the
recipient thereof in amounts typically used in medicaments.
[0066] Pharmaceutically acceptable carriers, adjuvants and vehicles
that may be used in the pharmaceutical compositions of this
invention include, but are not limited to, ion exchangers, alumina,
aluminum stearate, lecithin, serum proteins, such as human serum
albumin, buffer substances such as phosphates, glycine, sorbic
acid, potassium sorbate, partial glyceride mixtures of saturated
vegetable fatty acids, water, salts or electrolytes, such as
protamine sulfate, disodium hydrogen phosphate, potassium hydrogen
phosphate, sodium chloride, zinc salts, colloidal silica, magnesium
trisilicate, polyvinyl pyrrolidone, cellulose-based substances,
polyethylene glycol, sodium carboxymethylcellulose, polyacrylates,
waxes, polyethylene-polyoxypropylene-block polymers, polyethylene
glycol and wool fat.
[0067] The pharmaceutical compositions of the invention include
those suitable for oral, rectal, nasal, topical (including buccal
and sublingual), vaginal or parenteral (including subcutaneous,
intramuscular, intravenous and intradermal) administration. In
certain embodiments, the compound of the formulae herein is
administered transdermally (e.g., using a transdermal patch). Other
formulations may conveniently be presented in unit dosage form,
e.g., tablets and sustained release capsules, and in liposomes, and
may be prepared by any methods well known in the art of pharmacy.
See, for example, Remington's Pharmaceutical Sciences, Mack
Publishing Company, Philadelphia, Pa. (17th ed. 1985).
[0068] Such preparative methods include the step of bringing into
association with the molecule to be administered ingredients such
as the carrier that constitutes one or more accessory ingredients.
In general, the compositions are prepared by uniformly and
intimately bringing into association the active ingredients with
liquid carriers, liposomes or finely divided solid carriers or
both, and then if necessary shaping the product.
[0069] In certain preferred embodiments, the compound is
administered orally. Compositions of the present invention suitable
for oral administration may be presented as discrete units such as
capsules, sachets or tablets each containing a predetermined amount
of the active ingredient; as a powder or granules; as a solution or
a suspension in an aqueous liquid or a non-aqueous liquid; or as an
oil-in-water liquid emulsion or a water-in-oil liquid emulsion, or
packed in liposomes and as a bolus, etc. Soft gelatin capsules can
be useful for containing such suspensions, which may beneficially
increase the rate of compound absorption.
[0070] A tablet may be made by compression or molding, optionally
with one or more accessory ingredients. Compressed tablets may be
prepared by compressing in a suitable machine the active ingredient
in a free-flowing form such as a powder or granules, optionally
mixed with a binder, lubricant, inert diluent, preservative,
surface-active or dispersing agent. Molded tablets may be made by
molding in a suitable machine a mixture of the powdered compound
moistened with an inert liquid diluent. The tablets optionally may
be coated or scored and may be formulated so as to provide slow or
controlled release of the active ingredient therein. Methods of
formulating such slow or controlled release compositions of
pharmaceutically active ingredients, such as those herein and other
compounds known in the art, are known in the art and described in
several issued US patents, some of which include, but are not
limited to, U.S. Pat. Nos. 4,369,172; and 4,842,866, and references
cited therein. Coatings can be used for delivery of compounds to
the intestine (see, e.g., U.S. Pat. Nos. 6,638,534, 5,217,720, and
6,569,457, 6,461,631, 6,528,080, 6,800,663, and references cited
therein). A useful formulation for the compounds of this invention
is the form of enteric pellets of which the enteric layer comprises
hydroxypropylmethylcellulose acetate succinate.
[0071] In the case of tablets for oral use, carriers that are
commonly used include lactose and corn starch. Lubricating agents,
such as magnesium stearate, are also typically added. For oral
administration in a capsule form, useful diluents include lactose
and dried cornstarch. When aqueous suspensions are administered
orally, the active ingredient is combined with emulsifying and
suspending agents. If desired, certain sweetening and/or flavoring
and/or coloring agents may be added.
[0072] Compositions suitable for topical administration include
lozenges comprising the ingredients in a flavored basis, usually
sucrose and acacia or tragacanth; and pastilles comprising the
active ingredient in an inert basis such as gelatin and glycerin,
or sucrose and acacia.
[0073] Compositions suitable for parenteral administration include
aqueous and non-aqueous sterile injection solutions which may
contain anti-oxidants, buffers, bacteriostats and solutes which
render the formulation isotonic with the blood of the intended
recipient; and aqueous and non-aqueous sterile suspensions which
may include suspending agents and thickening agents. The
formulations may be presented in unit-dose or multi-dose
containers, for example, sealed ampules and vials, and may be
stored in a freeze dried (lyophilized) condition requiring only the
addition of the sterile liquid carrier, for example water for
injections, immediately prior to use. Extemporaneous injection
solutions and suspensions may be prepared from sterile powders,
granules and tablets.
[0074] Such injection solutions may be in the form, for example, of
a sterile injectable aqueous or oleaginous suspension. This
suspension may be formulated according to techniques known in the
art using suitable dispersing or wetting agents (such as, for
example, Tween 80) and suspending agents. The sterile injectable
preparation may also be a sterile injectable solution or suspension
in a non-toxic parenterally-acceptable diluent or solvent, for
example, as a solution in 1,3-butanediol. Among the acceptable
vehicles and solvents that may be employed are mannitol, water,
Ringer's solution and isotonic sodium chloride solution. In
addition, sterile, fixed oils are conventionally employed as a
solvent or suspending medium. For this purpose, any bland fixed oil
may be employed including synthetic mono- or diglycerides. Fatty
acids, such as oleic acid and its glyceride derivatives are useful
in the preparation of injectables, as are natural
pharmaceutically-acceptable oils, such as olive oil or castor oil,
especially in their polyoxyethylated versions. These oil solutions
or suspensions may also contain a long-chain alcohol diluent or
dispersant.
[0075] The pharmaceutical compositions of this invention may be
administered in the form of suppositories for rectal
administration. These compositions can be prepared by mixing a
compound of this invention with a suitable non-irritating excipient
which is solid at room temperature but liquid at the rectal
temperature and therefore will melt in the rectum to release the
active components. Such materials include, but are not limited to,
cocoa butter, beeswax and polyethylene glycols.
[0076] The pharmaceutical compositions of this invention may be
administered by nasal aerosol or inhalation. Such compositions are
prepared according to techniques well-known in the art of
pharmaceutical formulation and may be prepared as solutions in
saline, employing benzyl alcohol or other suitable preservatives,
absorption promoters to enhance bioavailability, fluorocarbons,
and/or other solubilizing or dispersing agents known in the
art.
[0077] Topical administration of the pharmaceutical compositions of
this invention is especially useful when the desired treatment
involves areas or organs readily accessible by topical application.
For application topically to the skin, the pharmaceutical
composition should be formulated with a suitable ointment
containing the active components suspended or dissolved in a
carrier. Carriers for topical administration of the compounds of
this invention include, but are not limited to, mineral oil, liquid
petroleum, white petroleum, propylene glycol, polyoxyethylene
polyoxypropylene compound, emulsifying wax and water.
Alternatively, the pharmaceutical composition can be formulated
with a suitable lotion or cream containing the active compound
suspended or dissolved in a carrier. Suitable carriers include, but
are not limited to, mineral oil, sorbitan monostearate, polysorbate
60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl
alcohol and water. The pharmaceutical compositions of this
invention may also be topically applied to the lower intestinal
tract by rectal suppository formulation or in a suitable enema
formulation. Topically-transdermal patches and iontophoretic
administration are also included in this invention.
[0078] Particularly favored derivatives and prodrugs are those that
increase the bioavailability of the compounds of this invention
when such compounds are administered to a mammal (e.g., by allowing
an orally administered compound to be more readily absorbed into
the blood) or which enhance delivery of the parent compound to a
biological compartment (e.g., the brain or central nervous system)
relative to the parent species. Preferred prodrugs include
derivatives where a group that enhances aqueous solubility or
active transport through the gut membrane is appended to the
structure of formulae described herein. See, e.g., Alexander, J. et
al. Journal of Medicinal Chemistry 1988, 31, 318-322; Bundgaard, H.
Design of Prodrugs; Elsevier: Amsterdam, 1985; pp 1-92; Bundgaard,
H.; Nielsen, N. M. Journal of Medicinal Chemistry 1987, 30,
451-454; Bundgaard, H. A Textbook of Drug Design and Development;
Harwood Academic Publ.: Switzerland, 1991; pp 113-191; Digenis, G.
A. et al. Handbook of Experimental Pharmacology 1975, 28, 86-112;
Friis, G. J.; Bundgaard, H. A Textbook of Drug Design and
Development; 2 ed.; Overseas Publ.: Amsterdam, 1996; pp 351-385;
Pitman, I. H. Medicinal Research Reviews 1981, 1, 189-214.
[0079] Application of the subject therapeutics may be local, so as
to be administered at the site of interest. Various techniques can
be used for providing the subject compositions at the site of
interest, such as injection, use of catheters, trocars,
projectiles, pluronic gel, stents, sustained drug release polymers
or other device which provides for internal access.
[0080] According to another embodiment, the invention provides a
method of impregnating an implantable drug release device
comprising the step of contacting said drug release device with a
compound or composition of this invention. Implantable drug release
devices include, but are not limited to, biodegradable polymer
capsules or bullets, non-degradable, diffusible polymer capsules
and biodegradable polymer wafers.
[0081] According to another embodiment, the invention provides an
implantable medical device coated with a compound or a composition
comprising a compound of this invention, such that said compound is
therapeutically active.
[0082] In another embodiment, a composition of the present
invention further comprises a second therapeutic agent. The second
therapeutic agent includes any compound or therapeutic agent known
to have or that demonstrates advantageous properties when
administered alone or with a compound of any of the formulae
herein. Drugs that could be usefully combined with these compounds
include other kinase inhibitors and/or other chemotherapeutic
agents for the treatment of the diseases and disorders discussed
above.
[0083] Such agents are described in detail in the art. Preferably,
the second therapeutic agent is an agent useful in the treatment or
prevention of a disease or condition selected from cancer.
[0084] Even more preferably the second therapeutic agent
co-formulated with a compound of this invention is an agent useful
in the treatment of kinase-mediated disease/disorders such as
cancer, immune disorders, cardiovascular disease, viral infection,
inflammation, metabolism/endocrine disorders and neurological
disorders.
[0085] In another embodiment, the invention provides separate
dosage forms of a compound of this invention and a second
therapeutic agent that are associated with one another. The term
"associated with one another" as used herein means that the
separate dosage forms are packaged together or otherwise attached
to one another such that it is readily apparent that the separate
dosage forms are intended to be sold and administered together
(within less than 24 hours of one another, consecutively or
simultaneously).
[0086] In the pharmaceutical compositions of the invention, the
compound of the present invention is present in an effective
amount. As used herein, the term "effective amount" refers to an
amount which, when administered in a proper dosing regimen, is
sufficient to reduce or ameliorate the severity, duration or
progression of the disorder being treated, prevent the advancement
of the disorder being treated, cause the regression of the disorder
being treated, or enhance or improve the prophylactic or
therapeutic effect(s) of another therapy.
[0087] The interrelationship of dosages for animals and humans
(based on milligrams per meter squared of body surface) is
described in Freireich et al., (1966) Cancer Chemother Rep 50: 219.
Body surface area may be approximately determined from height and
weight of the patient. See, e.g., Scientific Tables, Geigy
Pharmaceuticals, Ardley, N.Y., 1970, 537. An effective amount of a
compound of this invention can range from about 0.001 mg/kg to
about 500 mg/kg, more preferably 0.01 mg/kg to about 50 mg/kg, more
preferably 0.1 mg/kg to about 2.5 mg/kg. Effective doses will also
vary, as recognized by those skilled in the art, depending on the
diseases treated, the severity of the disease, the route of
administration, the sex, age and general health condition of the
patient, excipient usage, the possibility of co-usage with other
therapeutic treatments such as use of other agents and the judgment
of the treating physician.
[0088] For pharmaceutical compositions that comprise a second
therapeutic agent, an effective amount of the second therapeutic
agent is between about 20% and 100% of the dosage normally utilized
in a monotherapy regime using just that agent. Preferably, an
effective amount is between about 70% and 100% of the normal
monotherapeutic dose. The normal monotherapeutic dosages of these
second therapeutic agents are well known in the art. See, e.g.,
Wells et al., eds., Pharmacotherapy Handbook, 2nd Edition, Appleton
and Lange, Stamford, Conn. (2000); PDR Pharmacopoeia, Tarascon
Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing,
Loma Linda, Calif. (2000), each of which references are entirely
incorporated herein by reference.
[0089] It is expected that some of the second therapeutic agents
referenced above will act synergistically with the compounds of
this invention. When this occurs, its will allow the effective
dosage of the second therapeutic agent and/or the compound of this
invention to be reduced from that required in a monotherapy. This
has the advantage of minimizing toxic side effects of either the
second therapeutic agent of a compound of this invention,
synergistic improvements in efficacy, improved ease of
administration or use and/or reduced overall expense of compound
preparation or formulation.
Methods of Treatment
[0090] According to one aspect, the invention provides a method of
treating a subject suffering from or susceptible to a disease or
disorder or symptom thereof (e.g., those delineated herein)
comprising the step of administering to said subject an effective
amount of a compound (e.g., an isolated compound; a compound
herein) or a composition of this invention. Such diseases are well
known in the art and are also disclosed herein.
[0091] The methods can further comprise that wherein the
composition is an extract of Lycopodium clavatum (e.g., BCP-21
extracts, any of BCP-21 extract fractions in Tables 1 or 2) or an
isolated compound (e.g., 8-hydroxyhexadecanoic acid (8-HHA), any of
BCP compounds 1-10 herein) that occurs in a plant extract herein
(e.g., BCP-21 extracts, any of BCP-21 extract fractions in Tables 1
or 2).
[0092] In one embodiment of this invention the isolated compound is
8-hydroxyhexadecanoic acid ("8-HHA"), or a salt, prodrug, prodrug
salt, solvate, hydrate, and polymorph thereof. Certain embodiments
provide that the compound is a racemic mixture of R- and
S-enantiomers of 8-hydroxy-palmitic acid. In one embodiment, the
compound is the S-enantiomer of 8-hydroxy-palmitic acid
("(S)-8-HHA"). In another embodiment, the compound is the
R-enantiomer of 8-hydroxy-palmitic acid ("(R)-8-HHA").
[0093] In another embodiment, the compound (or compositions) used
in the methods of this invention is obtained through a synthetic
means.
[0094] In one aspect of this invention the disease or disorder is a
caspase mediated disease or disorder.
[0095] In one aspect of this invention the disease or disorder is
mediated by caspase-3 mediated cell death.
[0096] In one aspect of this invention the disease or disorder is a
caspase-3 mediated disease or disorder. In one aspect of this
invention the disease or disorder is treated by inducing cell
death.
[0097] In one aspect of this invention the disease or disorder is
treated by inducing cell death mediated by caspase-3.
[0098] In one aspect of this invention the disease or disorder can
be modulated by caspase-3.
[0099] In one aspect, the method of treating involves treatment of
a disorder that is a proliferation disorder or symptom thereof.
These include cancer, tumors, any disease wherein a neoplastic
agent is appropriate.
[0100] Examples of cancers which the present compounds,
compositions and methods of treatment can be used to treat include
cancer (e.g., leukemia, liver cancer, lung cancer, colon cancer,
CNS cancer, melanoma, renal cancer, and caspase-3 mediated
cancers), allergic and inflammatory disorders. A human or animal
patient suffering from a proliferation disorder, e.g., cancer, may
thus be treated by a method comprising the administration thereto
of a compound of the present invention as defined above. The
condition of the patient may thereby be improved or
ameliorated.
[0101] Diseases and conditions treatable according to the methods
of this invention include, but are not limited to, cancer and
inflammatory disorders. Cancers which can be treated according to
the methods of this invention include, but are not limited to
liver, hepatocellular, leukemia, lung, colon, CNS, melanoma, renal,
etc.
[0102] One embodiment provides that the cancer treatable according
to the methods of this invention is is a leukemia, lung cancer,
liver cancer, or colon cancer. In one embodiment, the cancer is a
liver cancer. Another embodiment provides that the cancer is a lung
cancer. In one embodiment, the lung cancer is a non-small cell lung
cancer. Certain instances provide that the cancer treatable
according to the methods of this invention relates to HOP-92
mediated diseases (e.g., non-small cell lung cancers).
[0103] Yet in another embodiment, the cancer which can be treated
according to the methods of this invention is a leukemia.
[0104] Methods delineated herein include those wherein the subject
is identified as in need of a particular stated treatment.
Identifying a subject in need of such treatment can be in the
judgment of a subject or a health care professional and can be
subjective (e.g. opinion) or objective (e.g. measurable by a test
or diagnostic method).
[0105] In one embodiment, the invention provides a method of
modulating the activity of a caspase enzyme (e.g., caspase-3) in a
cell comprising contacting a cell with one or more compounds of any
of the formulae herein.
[0106] In another embodiment, the above method of treatment
comprises the further step of co-administering to said patient one
or more second therapeutic agents. The choice of second therapeutic
agent may be made from any second therapeutic agent known to be
useful for indications herein.
[0107] The term "co-administered" as used herein means that the
second therapeutic agent may be administered together with a
compound of this invention as part of a single dosage form (such as
a composition of this invention comprising a compound of the
invention and an second therapeutic agent as described above) or as
separate, multiple dosage forms. Alternatively, the additional
agent may be administered prior to, consecutively with, or
following the administration of a compound of this invention. In
such combination therapy treatment, both the compounds of this
invention and the second therapeutic agent(s) are administered by
conventional methods. The administration of a composition of this
invention comprising both a compound of the invention and a second
therapeutic agent to a subject does not preclude the separate
administration of that same therapeutic agent, any other second
therapeutic agent or any compound of this invention to said subject
at another time during a course of treatment.
[0108] Effective amounts of these second therapeutic agents are
well known to those skilled in the art and guidance for dosing may
be found in patents and published patent applications referenced
herein, as well as in Wells et al., eds., Pharmacotherapy Handbook,
2nd Edition, Appleton and Lange, Stamford, Conn. (2000); PDR
Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition,
Tarascon Publishing, Loma Linda, Calif. (2000), and other medical
texts. However, it is well within the skilled artisan's purview to
determine the second therapeutic agent's optimal effective-amount
range.
[0109] In one embodiment of the invention where a second
therapeutic agent is administered to a subject, the effective
amount of the compound of this invention is less than its effective
amount would be where the second therapeutic agent is not
administered. In another embodiment, the effective amount of the
second therapeutic agent is less than its effective amount would be
where the compound of this invention is not administered. In this
way, undesired side effects associated with high doses of either
agent may be minimized. Other potential advantages (including
without limitation improved dosing regimens and/or reduced drug
cost) will be apparent to those of skill in the art.
[0110] In yet another aspect, the invention provides the use of a
compound of any of the formulae herein alone or together with one
or more of the above-described second therapeutic agents in the
manufacture of a medicament, either as a single composition or as
separate dosage forms, for treatment or prevention in a subject of
a disease, disorder or symptom set forth above. Another aspect of
the invention is a compound of the formulae herein for use in the
treatment or prevention in a subject of a disease, disorder or
symptom thereof delineated herein.
[0111] In other aspects, the methods herein include those further
comprising monitoring subject response to the treatment
administrations. Such monitoring may include periodic sampling of
subject tissue, fluids, specimens, cells, proteins, chemical
markers, genetic materials, etc. as markers or indicators of the
treatment regimen. In other methods, the subject is prescreened or
identified as in need of such treatment by assessment for a
relevant marker or indicator of suitability for such treatment.
[0112] In one embodiment, the invention provides a method of
monitoring treatment progress. The method includes the step of
determining a level of diagnostic marker (Marker) (e.g., any target
or cell type delineated herein modulated by a compound herein) or
diagnostic measurement (e.g., screen, assay) in a subject suffering
from or susceptible to a disorder or symptoms thereof delineated
herein, in which the subject has been administered a therapeutic
amount of a compound herein sufficient to treat the disease or
symptoms thereof. The level of Marker determined in the method can
be compared to known levels of Marker in either healthy normal
controls or in other afflicted patients to establish the subject's
disease status. In preferred embodiments, a second level of Marker
in the subject is determined at a time point later than the
determination of the first level, and the two levels are compared
to monitor the course of disease or the efficacy of the therapy. In
certain preferred embodiments, a pre-treatment level of Marker in
the subject is determined prior to beginning treatment according to
this invention; this pretreatment level of Marker can then be
compared to the level of Marker in the subject after the treatment
commences, to determine the efficacy of the treatment.
[0113] In certain method embodiments, a level of Marker or Marker
activity in a subject is determined at least once. Comparison of
Marker levels, e.g., to another measurement of Marker level
obtained previously or subsequently from the same patient, another
patient, or a normal subject, may be useful in determining whether
therapy according to the invention is having the desired effect,
and thereby permitting adjustment of dosage levels as appropriate.
Determination of Marker levels may be performed using any suitable
sampling/expression assay method known in the art or described
herein. Preferably, a tissue or fluid sample is first removed from
a subject. Examples of suitable samples include blood, urine,
tissue, mouth or cheek cells, and hair samples containing roots.
Other suitable samples would be known to the person skilled in the
art. Determination of protein levels and/or mRNA levels (e.g.,
Marker levels) in the sample can be performed using any suitable
technique known in the art, including, but not limited to, enzyme
immunoassay, ELISA, radiolabelling/assay techniques,
blotting/chemiluminescence methods, real-time PCR, and the
like.
Use of Compounds of this Invention
[0114] The present invention also provides kits for use to treat
diseases, disorders, or symptoms thereof, including those
delineated herein. These kits comprise: a) a pharmaceutical
composition comprising one or more compounds of any of the formula
herein (e.g., composition herein, any specific compound herein) or
a salt thereof; or a prodrug, or a salt of a prodrug thereof; or a
hydrate, solvate, or polymorph thereof, wherein said pharmaceutical
composition is in a container; and b) instructions describing a
method of using the pharmaceutical composition to treat the
disease, disorder, or symptoms thereof, including those delineated
herein. The compounds/compositions can be administered sequentially
or concurrently with radiation treatment administration.
[0115] The container may be any vessel or other sealed or sealable
apparatus that can hold said pharmaceutical composition. Examples
include bottles, divided or multi-chambered holders bottles,
wherein each division or chamber comprises a single dose of said
composition, a divided foil packet wherein each division comprises
a single dose of said composition, or a dispenser that dispenses
single doses of said composition. The container can be in any
conventional shape or form as known in the art which is made of a
pharmaceutically acceptable material, for example a paper or
cardboard box, a glass or plastic bottle or jar, a re-sealable bag
(for example, to hold a "refill" of tablets for placement into a
different container), or a blister pack with individual doses for
pressing out of the pack according to a therapeutic schedule. The
container employed can depend on the exact dosage form involved,
for example a conventional cardboard box would not generally be
used to hold a liquid suspension. It is feasible that more than one
container can be used together in a single package to market a
single dosage form. For example, tablets may be contained in a
bottle, which is in turn contained within a box. Preferably, the
container is a blister pack.
[0116] The kit may additionally comprise information and/or
instructions for the physician, pharmacist or subject. Such memory
aids include numbers printed on each chamber or division containing
a dosage that corresponds with the days of the regimen which the
tablets or capsules so specified should be ingested or administered
to a subject, or days of the week printed on each chamber or
division, or a card which contains the same type of information. In
one aspect, the instructions further relate to radiation
administration to the subject.
[0117] In yet another aspect, this invention provides the use of a
compound (or a combination of compounds) of the invention, alone or
together with one or more additional therapeutic agents in the
manufacture of a medicament, either as a single composition or as
separate dosage forms, for treatment or prevention in a subject of
a disease, disorder or symptom set forth herein. Another aspect of
the invention is a compound (or a combination of compounds) of the
invention for use in the treatment or prevention in a subject of a
disease, disorder or symptom thereof delineated herein.
[0118] All references cited herein, whether in print, electronic,
computer readable storage media or other form, are expressly
incorporated by reference in their entirety, including but not
limited to, abstracts, articles, journals, publications, texts,
treatises, technical data sheets, internet web sites, databases,
patents, patent applications, and patent publications.
EXAMPLES
General Procedures
[0119] NMR spectra were acquired on a JEOL ECLIPSE 400 MHz NMR
spectrometer referenced to the solvent used (CDCl.sub.3). ESI-MS
(negative mode) was obtained with Hitachi M-8000 mass spectrometer.
Analysis was performed using an Agilent Model 5971A mass
spectrometer (range: 70-550 amu) with a Phenomenex ZB-WAX-column
(300 m.times.0.32 mm.times.0.25 m) and an Agilent Model 5890 gas
chromatography.
[0120] HPLC Assay Method 1 (Reversed Phase Method): This gradient
method can be used to assay the extract and column fractions. The
column is a 4.6.times.100 mm, Phenomenex Luna(2), 3.mu. C18 column
(PIN 00D-4251-EO). Flow rate 1.0 mL/min; Temp. 40.degree. C.,
injection 10 uL. Detection is ELSD and UV at 200 nm. Normal-phase
chromatography samples are evaporated and reconstituted in acetone
before being injected. HPLC Assay Method 2 (Normal Phase Method):
This gradient method can be used to assay column fractions and
final products. The column is a 4.6.times.250 mm, 5.mu., Alltech,
Adsorbosil Silica Column (P/N 298017). Mobile phases: Hexane/EtOAc,
Flow rate 1.0 mL/min; Temp. 40.degree. C., injection 10 uL.
Detection is ELSD. Normal-phase chromatography samples can be
injected directly, and solid sample are reconstituted in EtOAc
before being injected. Acetone solution could give a broad or
double peak. Bioassay for apoptotic activity of HPLC fractions: One
hundred thousand HeLa cells/well, were plated in 24 well cell
culture plates. The cells were grown for 24 hours in cell culture
incubator. After 24 hours the cells were treated with compounds
derived from BCP21 purification. Fractions generated by HPLC during
the purification were dried and re-suspended in DMSO. The cells
were treated with three different concentrations of compounds in
each fraction. The cells were harvested after 24 hours to determine
the % apoptosis (cell death). The cells were treated with trypan
blue to estimate the cell death. Cell death less than 10% was
marked as + while 100% was represented by ++++, 50 and 75% were
marked with ++ and +++ respectively.
Example 1. Extraction and Isolation from Lycopodium clavatum
Isolation of BCP-21
[0121] Spores of Lycopodium clavatum are extracted using 95%
ethanol. The resulting extractive phases are combined and may be
stored as solutions in 95% ethanol or can be concentrated.
Evaporation and Partitioning of the Extract: BCP21 ethanol solution
(1 L) was evaporated at 45.degree. C. under vacuum to give a
suspension which contained small amount of precipitate. 50 mL water
was added to the suspension, and partitioned with 200 mL methylene
chloride (MC). The MC layer was separated in a separatory funnel,
and evaporated to dryness, giving 18.9 g of oily residue. The water
layer was dried to give 2.84 g solids. HPLC profiles of the BCP21
ethanol extract and the MC soluble residue were done.
Example 2. 40M Silica Biotage Fractionation
[0122] Since bioassays indicated that the aforementioned MC-soluble
residue contained the active compounds, 5 g of this material was
dissolved in 15 mL MC, and loaded onto a 40 M silica cartridge
which had been equilibrated with 800 mL hexane. The column was
eluted with 10% acetone/hexane (A/H) (1 L), 20% A/H (1 L), 25% A/H
(1.2 L), and acetone (0.5 L). Based on bioassay results, F5 to F8,
and F9 to F11 of the 25% A/H eluate were combined and dried by a
stream of nitrogen to give 2615-182-8 (43.4 mg) and 2615-182-9
(36.3 mg), respectively. Table 1 details fraction sampling results
guided by apoptotic assaying.
TABLE-US-00001 TABLE 1 Weights and Bioassay Results of the
Fractions from 40M Column Sample Sampling for # Fraction Weight
(mg) Bioassay (mg) Bioassay Result 1 10% A/H Fl 2980.8 78.6 + 2 F2
601.2 53.6 + 3 F3 39.8 10.8 + 4 F4 32.4 5.4 + 5 20% A/H Fl 87.0
12.4 ++ 6 F2 110.6 13.7 + 7 F3 62.1 6.4 ++ 8 F4 193.2 35.5 ++ 9 F5
93.2 18 ++ 10 25% A/H F1 14.4 5.2 ++ 11 F2 14.3 2.9 ++ 12 F3 19.1
3.0 ++ 13 F4 15.9 3.1 +++ 14 F5 13.9 2.4 ++++ 15 F6 13.4 2.0 ++++
16 F7 13.3 1.7 ++++ 17 F8 13.4 2.0 ++++ 18 F9 14.1 1.5 ++++ 19 F10
12.2 1.6 ++++ 20 F11 10.2 2.0 ++++ 21 Acetone F1 52.5 7.0 +++ 22 F2
33.5 3.6 +
Example 3. 12M Silica Biotage Fractionation
[0123] The aforementioned active pooled product 2615-182-8(43.4 mg)
was dissolved in 2 mL 30% EtOAc/hexane at 50.degree. C. and the
solution injected onto a 12 M Biotage silica cartridge equilibrated
with 100 mL 30% EtOAc/hexane. The column was eluted with 60 mL of
35% EtOAc/hexane, 100 mL of 40% EtOAc/hexane, 60 mL of 45%
EtOAc/hexane, 60 mL of 80% EtOAc/hexane yielding 26 fractions. 1 mL
each was sent for bioassays after drying. The remaining solution of
each fraction was dried to get the weights. Table 2 details
fraction sampling results guided by apoptotic assaying.
TABLE-US-00002 TABLE 2 Weights and Bioassay Results of the
Fractions from 12M Column Sample # Fraction Weight (mg) Bioassay
Result 1 35% EtOAc/HexaneFl 2.5 - 2 F2 0.14 - 3 F3 0 - 4 F4 0 - 5
40% EtOAc/HexaneFl 0.27 - 6 F2 0.44 ++ 7 F3 0.67 ++ 8 F4 0.71 +++ 9
F5 0.72 +++ 10 F6 0.69 +++ 11 F7 0.59 +++ 12 F8 0.48 +++ 13 F9 0.85
++ 14 F10 0.51 ++ 15 45% EtOAc/HexaneF1 0.67 + 16 F2 0.44 - 17 F3
0.63 - 18 F4 0.82 + 19 F5 0.64 - 20 F6 0.45 - 21 80% EtOAc/HexaneFl
0.59 - 22 F2 1.00 + 23 F3 2.72 +++ 24 F4 3.25 +++ 25 F5 1.60 +++ 26
F6 1.23 +++
TABLE-US-00003 TABLE 3 BCP-Compound BCP-Compound Table 2 Sample(s)
1 1 2 3 3 7 4 13 5 14 6 18 7 22 8 -- 9 -- 10 --
Example 4. Preparation of Test Compound Samples for Assay
[0124] Preparation of the aforementioned compound fractions was
performed according to that delineated in Table 4 as follows:
TABLE-US-00004 TABLE 4 Compound Preparation & Dilution 2% 1%
0.50% BCP- 80 .mu.l of Compound 1 + 3920 .mu.l of Media 2000 .mu.l
of 2% Comp1 + 2000 .mu.l of Media 2000 .mu.l of 1% Comp1 + 2000
.mu.l of Media Compound 1 BCP- 80 .mu.l of Compound 2 + 3920 .mu.l
of Media 2000 .mu.l of 2% Comp2 + 2000 .mu.l of Media 2000 .mu.l of
1% Comp2 + 2000 .mu.l of Media Compound 2 BCP- 80 .mu.l of Compound
3 + 3920 .mu.l of Media 2000 .mu.l of 2% Comp3 + 2000 .mu.l of
Media 2000 .mu.l of 1% Comp3 + 2000 .mu.l of Media Compound 3 BCP-
80 .mu.l of Compound 4 + 3920 .mu.l of Media 2000 .mu.l of 2% Comp4
+ 2000 .mu.l of Media 2000 .mu.l of 1% Comp4 + 2000 .mu.l of Media
Compound 4 BCP- 80 .mu.l of Compound 5 + 3920 .mu.l of Media 2000
.mu.l of 2% Comp 5 + 2000 .mu.l of Media 2000 .mu.l of 1% Comp5 +
2000 .mu.l of Media Compound 5 BCP- 80 .mu.l of Compound 6 + 3920
.mu.l of Media 2000 .mu.l of 2% Comp6 + 2000 .mu.l of Media 2000
.mu.l of 1% Comp6 + 2000 .mu.l of Media Compound 6 BCP- 80 .mu.l of
Compound 7 + 3920 .mu.l of Media 2000 .mu.l of 2% Comp 7 + 2000
.mu.l of Media 2000 .mu.l of 1% Comp7 + 2000 .mu.l of Media
Compound 7 BCP- 80 .mu.l of Compound 8 + 3920 .mu.l of Media 2000
.mu.l of 2% Comp8 + 2000 .mu.l of Media 2000 .mu.l of 1% Comp8 +
2000 .mu.l of Media Compound 8 BCP- 80 .mu.l of Compound 9 + 3920
.mu.l of Media 2000 .mu.l of 2% Comp9 + 2000 .mu.l of Media 2000
.mu.l of 1% Comp9 + 2000 .mu.l of Media Compound 9 BCP- 80 .mu.l of
Compound 10 + 3920 .mu.l of Media 2000 .mu.l of 2% Comp 10 + 2000
.mu.l of Media 2000 .mu.l of 1% Comp10 + 2000 .mu.l of Media
Compound 10 BCP-DMSO 80 .mu.l of DMS0 + 3920 .mu.l of Media 2000
.mu.l of 2% DMSO + 2000 .mu.l of Media 2000 .mu.l of 1% DMSO + 2000
.mu.l of Media
Example 5. Synthesis of Racemic 8-Hydroxypalmitic Acid
("8-HHA")
##STR00001##
[0125] Scheme for the Synthesis of Racemic 8-Hydroxypalmitic
Acid
[0126] Two three necked flasks are equipped with gas inlet adaptor,
septa and stir bars and then flasks were purged with Argon. Suberic
acid monomethyl ester (10.0 g, 53.1 mmol, 1 equiv) was dissolved in
THF (380 mL, 0.17M) in one flask. Triethylamine (0.95 mL, 64.1
mmol, 1.2 equiv) added gradually (over 4 min, using gas-tight
syringe) and the mixture was stirred at room temperature for 1.25
h. A separate solution was made from PPh.sub.3Cl.sub.2 (24.4 g,
73.2 mmol, 1.4 equiv) in anhydrous DCM which is then cooled to
<30.degree. C. The suberic acid solution was added drop wise to
the yellow PPh.sub.3Cl.sub.2 solution and stirred for 2 h at -35 to
-20.degree. C. The Grignard reagent was then added drop wise over
45 min while maintaining temperature -41 to -7.degree. C. The
reaction mixture stirred for 1.5 h, and then was quenched while
still cold with 2N HCl (75 mL). After stirring for 20 min the
yellow color fades. Thin later chromatography (silica gel 60, 25%
acetone/hexanes) to give a reaction mixture as two major product
spots plus PPh.sub.3 and OPPh.sub.3.
[0127] The reaction mixture was added to a reparatory funnel along
with ethyl acetate (200 mL) and 2N HCl (200 mL). The organic layer
was collected and the aqueous layer was back-extracted with
2.times.80 mL ethyl acetate. The combined organic phases were
neutralized by washing with NaHCO.sub.3(saturated solution,
2.times.90 mL), then washed with brine, (90 mL) dried over
MgSO.sub.4 (20 g, 30 min), filtered, rotoevaporated at 25.degree.
C. and dried under high vacuum for 3 h. To remove ethyl acetate the
material is mixed with 20 mL DCM and re-evaporated to give 33 g of
crude material.
[0128] The crude material is taken up in 10% acetone/DCM and loaded
on a silica gel plug (240 mL) and flushed with 4CV of 10%
acetone/DCM. The first plug removed 10.4 g of OPPh.sub.3 and a
second removed 6.8 g of OPPI1.sub.3. Purification continued with
flash column chromatography, in which a 5.times.29 cm column is
packed with Silica gel 60 in 10% acetone/hexanes. The crude
material was loaded in a minimum volume of 55% DCM/hexanes. Desired
compound is eluted with 10% DCM/5% acetone/85% hexanes. Evaporation
and drying of one fraction gives 2.7 g compound 1 (8-ketopalinitic
acid methyl ester), and a repeat column on several impure fractions
gave another 2.0 g compound 1. Overall yield was 31% based on
suberic acid mono methyl ester. Compound 1 (8-ketopaimitic acid
methyl ester) was characterized by .sup.1H NMR (in CDCl.sub.3):
3.65 (s, 3H, OCH.sub.3), 2.37. (m, 2H, O.dbd.CCH.sub.2), 2.29 (t,
2H, O.dbd.CCH.sub.2), 1.57 and 1.28, (br., 22H, CH.sub.2), 0.87 (s,
3H, CH.sub.3-terminal).
[0129] Compound 1 (2.86 g, 10.1 mmol) was dissolved in 50 mL
ethanol and cooled in an ice bath. The sodium borohydride (1.9 g,
59.5 mmol) was added in portions at 1-17 C. The reaction was
monitored by TLC (plates developed in 25% acetone/hexanes) where Rf
was 0.56 for the ketone and 0.28 for the methyl ester. Additional
portions of solid NaBH.sub.4 were added over a 2 h period (total of
60 eq used) until no starting material was detected. The reaction
was quenched by slowly adding 2N HCl (60 mL) to the cold solution,
transferred to a separatory funnel and washed with DCM (3.times.35
mL). The combined organic layers were washed with
NaHCO.sub.3(saturated, 35 mL) and brine (35 mL), then dried over
MgSO.sub.4 (7 g, 30 min) filtered and rotoevaporated to give a
clear oil, which became a white waxy solid when stored at 4.degree.
C. (Yield 2.86 g).
[0130] The material was purified by flash chromatography (Silica
gel 60, 20% acetone/heptane). After rotoevaporating to dryness the
compound is an oil, and after drying on high vacuum the product is
a white waxy solid. The .sup.1H NMR spectra (CDCl.sub.3) showed the
predominant product as Compound 2 with small amounts of unknown
impurities. Compound 2 (8-hydroxypalmitic acid methyl ester) was
characterized by .sup.1H NMR (in CDCl.sub.3): 3.66 (s, 3H,
OCH.sub.3), (br, 1H, methine), 2.29 (t, 2H, O.dbd.CCH.sub.2), 1.62
and 1.31, (br., 28H, CH.sub.2), 0.87 (s, 3H,
CH.sub.3-terminal).
[0131] Compound 2 (1.97 g, 6.9 mmol) was dissolved in THF (28 mL).
Lithium hydroxide was dissolved in water (Nanopure, 15 mL) and
stirred 5 min. to dissolve. The LiOH solution was added slowly over
5 min to the ester solution and stirred at room temperature. The
reaction was monitored by TLC (20% acetone/hexane) until the
product disappeared and a new spot appeared at baseline (4 h). Work
up involved rotoevaporating the reaction mixture to remove
volatiles to get abundant white solids. The solids were rinsed with
DCM, then combined with 2N HCl (solids mostly insoluble) and
chloroform. The aqueous layer was extracted with CHCl.sub.3
(3.times.75 mL).sup.3. Combined organic phases were dried with
brine and MgSO.sub.4 (30 min) then filtered, rotoevaporated and
dried under high vacuum overnight to give 1.67 g of white solid as
the final product (89% yield).
[0132] Analysis of the final product supported its identification
as 8-hydroxy-palmitic acid, as the predominant product. .sup.1H NMR
(in CDCl.sub.3): 5.5 (very broad, 1H, OH) (3.58 br, 1H, methine),
2.34 (t, 2H, O.dbd.CCH.sub.2), 1.64 and 1.33, (br., 28H, CH.sub.2),
0.87 (s, 3H, CH.sub.3-terminal). .sup.13C NMR (in CDCl.sub.3):
178.40, 72.08, 37.59, 37.43, 33.79, 31.97, 29.79, 29.68, 29.37,
29.09, 25.73, 25.51, 24.69, 22.76, 14.20. LC-MS (ESI-mode in
ACN-NH.sub.4011). Parent ion 271.13 m/z, theory: 272 (100%) 273
(17%). Melting point: 70.5.degree. C.
Example 6. Synthesis of Both (S)- and (R)-8-Hydroxypalmitic
Acid
##STR00002##
[0134] The reaction of racemic 1,2-decanediols with
p-toluenesulfonyl chloride in the presence of base is known to give
a mixture of the desired primary tosylate, bis-tosylate, and minor
amounts of the secondary tosylate (Bull. Korean Chem. Soc. 2009
Vol. 30, No. 7, 1671-4). The generation of any secondary tosylate
could adversely affect the stereochemical purity of the resulting
epoxide due to inversion of the stereocenter during ring closure at
the 2-position.
[0135] In this reaction, 23.9 ml (0.172 mol, 3.0 equiv.) of
triethylamine in 10 ml of anhydrous dichloromethane was added
slowly over a 40 minute period to a solution of 10.00 g (0.0574
mol) 1,2(S)-decanediol (99.5% "S"), 13.7 g (0.0717 mol, 1.25
equiv.) p-toluenesulfonyl chloride, 0.70 g (0.00574 mol, 0.10
equiv.), and 30 ml of anhydrous dichloromethane at <10.RTM. C.
After stirring for 20 minutes at <10.degree. C. the reaction was
complete by TLC (100% CH.sub.2C.sub.12). After warming to room
temperature, the product mixture was partitioned into the organic
phase by the addition of 200 ml MTBE and 120 ml of 1M HCl. The
organic layer was washed 1.times.80 ml sat'd. NaHCO.sub.3 solution,
1.times.80 ml water, and 1.times.80 ml sat'd. NaCl solution. Drying
over sodium sulfate and concentration resulted in 21.7 g of residue
that was carried directly on to the conversion to the epoxide. This
residue was dissolved in 217 ml of anhydrous THF and 9.64 g (0.086
mol, 1.30 equiv.) of potassium t-butoxide was added at room
temperature without cooling. After 30 minutes, the reaction was
complete by TLC (10:1 heptane/ethyl acetate). The reaction was
quenched by the addition of 100 ml water and the THF was removed in
vacuo. The product mixture was partitioned into 300 ml MTBE and the
aqueous layer back extracted 1.times.50 ml MTBE. The combined
organics were then washed with 1.times.80 ml sat'd. NaCl solution.
Drying over sodium sulfate and concentration resulted in 10.4 g of
residue. The residue was short-path distilled and the
1,2(S)-epoxydecane was collected at ca. 60.degree. C. and 1 mmg Hg.
6.11 g resulted for a 68% recovery with a GC-MS purity of
>99%.
##STR00003##
[0136] The formation of and addition of the Grignard reagents to
racemic or chiral 1,-epoxydecane was performed according to a
literature procedure (J. Org. Chem. 2009, 74, 5063-5066). The
Grignards were prepared at ca. 0.5 M at <10.degree. C. in order
to minimize self-coupling products. No effort to titrate the
Grignard reagents was made, and they were assumed to be 0.5 M. The
addition of I.sub.2 was not required in order to activate the
magnesium turnings to get the Grignard reactions started.
[0137] To a dry 250 ml flask under N.sub.2, charge 98 ml (0.049
mol, 1.5 equiv.) hept-6-enylmagnesium bromide ca. 0.5 M in THF (as
prepared above). Cool the contents of the flask to -40.degree. C.
with stirring. Charge 1.24 g (0.00653 mol, 0.20 equiv.) of copper
(I) iodide to the flask. After 0.5 hours at -40.degree. C., slowly
add a solution of 5.10 g (0.0326 mol) 1,2(S)-epoxydecane in 51 ml
of anhydrous THF over at least 1 hour at -40.+-.5.degree. C.
Continue to stir at -40.degree. C. for 2 hours after the addition
is complete after which the reaction is typically complete by TLC
(40% EtOAc in heptane). After completion, 500 ml of MTBE, 125 ml of
saturated ammonium chloride and 50 ml of water are added and mixed
well for 15 minutes. Layers are cut and the organics are washed
with 100 ml a mixture of 1 part saturated ammonium chloride and 1
part water. The organics are then washed 3.times.100 ml water, lx
50 ml saturated NaCl solution, dried over sodium sulfate, filtered,
and concentrated to an oil which solidifies upon standing (8.6 g
results). The product is chromatographed on 220 g of silica first
eluting with 500 ml of heptane to remove any non-polar impurities,
then with 10:1 (v:v) heptane/ethyl acetate. The product containing
fractions are pooled and concentrated to give 8.11 g (97.6% yield)
of 9(S)-hydroxyheptadec-1-ene as a waxy solid that is 96.7% pure by
GC-MS.
##STR00004##
[0138] The protection of the alcohol was accomplished by the
addition of 1.50 equiv. of t-butyldimethylsilyl chloride to a THF
solution of the alkenols with 2.0 equiv. of imidazole as base.
Typically, after 16-20 h at room temperature, the reaction was
92-96% complete. Additional TBS chloride and imidazole did not
drive the reaction all the way to completion. Acidic aqueous
work-up with partitioning into heptane allowed for the removal of
imidazole without decomposition of the acid sensitive TBS protected
alcohol. Flash chromatography with heptane on silica easily removed
the residual unreacted alcohol and allowed the intermediates to be
isolated with high purities (>99% by GC-MS) (NB 1362-42, 45, 86;
1341-89; 1380-15).
##STR00005##
[0139] A solution of 9.83 g (0.0267 mol) of
9(S)-(t-butyldimethylsilyloxy)heptadec-1-ene, 0.10 g (0.00027 mol,
0.01 equiv.) Sudan red 7B in 138 ml of dichloromethane and 138 ml
of methanol was treated with ozone at -25.+-.5.degree. C. Ozone
addition was continued for another 6-7 minutes after the color of
the indicator has discharged. The solution is then sparged with
N.sub.2 for at least 30 min. A solution of 13.99 g (0.0533 mol,
2.00 equiv.) of triphenylphosphine was then added over 4-5 minutes
at <-15.degree. C. and then allowed to warm to room temperature.
After stirring for 30 minutes at room temperature the reaction is
checked by GC-MS and checked again at 1.25 and 3 hours. All three
checks typically indicate the same levels of triphenylphosphine,
triphenylphosphine oxide, and product showing that the ozonide has
been consumed. The reaction mixture is then concentrated to a pasty
solid, and re-concentrated one time from 100 ml of dichloromethane
(in order to remove methanol). The residue was then chromatographed
on 300 g of silica eluting with heptane followed by 20:1
heptane/ethyl acetate. The product containing fraction are pooled
and concentrated to give 13 g of oil that still contains 31%
triphenylphosphine by GC-MS. The oil was re-chromatographed on 500
g of silica and the triphenylphosphine level was now 13%. This oil
was dissolved in 100 ml of dichloromethane. 0.46 ml (0.0074 mol) of
iodomethane was added and the mixture was stirred overnight after
which all of the triphenylphosphine had been consumed (monitored by
GC-MS). Finally, the product was flash chromatographed on 200 g of
silica eluting with 10:1 heptane/ethyl acetate. After
concentration, 8.00 g (89% yield) of
8(S)-(t-butyldimethylsilyloxy)hexadecanal was resulted with a GC-MS
purity of 98.7%.
[0140] To a solution of 3.79 g (0.0102 mol)
8(S)-(t-butyldimethylsilyloxy)hexadecanal in 315 ml of t-butanol
was added at room temperature over 30 minutes, a solution of 8.49 g
(0.0939 mol, 9.17 equiv.) sodium chlorite and 8.50 g (0.0708 mol)
sodium dihydrogenphosphate in 125 ml of water. The mild exotherm
was controlled by a water bath. After stirring overnight, the
reaction was complete by TLC (1:1:0.01 Heptane: EtOAc: HOAc). The
t-butanol was removed in vacuo. The residue was dissolved in 200 ml
water and 300 ml heptane and then 80 ml of 1.0 M HCl was added. The
resulting heptane layer was washed 3.times.100 ml water, 1.times.75
ml saturated sodium chloride solution, dried over sodium sulfate,
filtered and concentrated to give 3.79 g (95.7% yield) of
8(S)-(t-butyldimethylsilyloxy)hexadecanoic acid 99.4% purity by
GC-MS (as the methyl ester from TMSCHN.sub.2).
##STR00006##
[0141] 3.79 g (0.00980 mol) of
8(S)-(t-butyldimethylsilyloxy)hexadecanoic acid, 48 ml of ACN, and
2.13 ml (0.059 mol, 6 equiv.) of 48% hydrofluoric acid were
combined and stirred for 1 hour. After 20-30 minutes the oily
mixture becomes a suspension. After 1 hour, the starting material
was completely consumed (as monitored by TLC (1:1:0.01 Heptane:
EtOAc: HOAc)). Upon completion, 300 ml of MTBE and 300 ml of water
were added and mixed thoroughly. The aqueous layer was removed and
the organic layer washed 3.times.100 ml water, 1.times.100 ml
saturated sodium chloride, dried over sodium sulfate, filtered and
concentrated to give 2.50 g of solid. The solid was 95.6% ee at
this point (NB 1380-51). The solid was dissolved in 40 ml of hot
ACN and allowed to cool with stirring. The resulting suspension was
cooled to <10.degree. C. for 30 minutes, collected by
filtration, washed with 20 ml cold ACN, and was dried under vacuum
at 40.degree. C. to give 2.18 g (82% yield) of 8(S)-hydroxypalmitic
acid, that was >99% by GC-MS (as the methyl ester from
TMSCHN.sub.2) and 98.4% ee by HPLC-MS.
##STR00007##
[0142] To invert the stereo center of 8-hydroxyacid under Mitsunobu
conditions, the carboxylic acid had to be protected as its methyl
ester. Initially on small scale, diazomethane was used as a quick
efficient method of conversion. Due to the dangerous nature of
diazomethane, a safer alternative, TMS diazomethane, was used on
the larger scale. 2.6 equivalents of TMS diazomethane were required
to fully esterify the acid in MTBE/methanol. Attempts to invert the
stereo center under Mitsunobu conditions using acetic acid proved
less than ideal. The same conditions substituting 4-nitrobenzoic
acid (Organic Synthesis, Collective Volume 9, page 607) provided
the 8(R)-4-nitrobenzoate cleanly. Saponification using LiOH in
THF/water followed by recrystallization from ACN provided the
desired 8(R)-hydroxypalmitic acid that was 100% ee by HPLC-MS.
Example 7: General Assay Procedure for Determination of HeLa Cell
Viability by Alamar Blue Assay
[0143] Assessment of cell viability by alamar blue reduction method
is routinely used for illustrating cytotoxic potential of candidate
drugs. Alamar blue detects cell viability by utilizing a blue
non-fluorescent dye resazurin, which is converted to a pink
fluorescent dye, resorufin by cellular metabolic intermediates. The
fluorescent signal generated from the assay is proportional to the
number of living cells in the sample. Confluent HeLa cells (70-80%)
grown in T-75 flasks were detached using trypsin-EDTA. Following
centrifugation, the cells pellet was resuspended in DMEM medium and
counted using a hemocytometer. Cells were seeded into 96 well plate
at a density of 10,000 cells/100 .mu.l/well and incubated at
37.degree. C./5% CO.sub.2 for 8 hrs. Media was removed and test
compounds were added in the volume of 100 The plate was incubated
for 22, 46 &70 hrs, after which 10 .mu.l of alamar blue was
added per well. At the end of 24, 48 & 72 hrs treatment with
test compound, fluorescence was measured at 530 excitation and 590
nm emissions using a micro plate reader. Viability expressed as %
control was plotted against drug concentration. Terfenadine was
used as a reference compound in the protocol and showed a dose
dependent inhibition in all the time points (24, 48 and 72 hrs)
with reproducible IC50 values. Different compounds showed different
viability.
Example 8: Data Analysis of Example 7 Assays
[0144] The mean value of duplicate wells was calculated. Viability
of control cells was considered as 100% for all test
concentrations. The percentage of cell viability of test samples
was calculated as:
% Viability = 100 .times. Fluorescence Units of Test Fluorescence
Units of Control ##EQU00001##
IC.sub.50 values were determined by nonlinear regression analysis
(curve fit) of percent viability data against drug concentration
using the sigmoidal dose-response (variable) equation (Graph Pad
Prism 4 software). BCP-6 and BCP-7 demonstrated particular effect
on cells. Quality Control: The assay was evaluated for following
quality checks: [0145] i. IC.sub.50 Value of Reference Compound:
IC.sub.50 value of Terfenadine [0146] ii. % Coefficient of Variance
between Replicates: The % CV between replicates was within the
acceptable limits (10%).
Example 9. Preparation of Test Compound Samples. Preparation of the
Aforementioned Compound Fractions was Performed According to that
Delineated in Table 5
Table 5: Compound Preparation & Dilution
TABLE-US-00005 [0147] TABLE 5 Compound Preparation & Dilution
BCP-21 cmpd 2% 1.00% 0.50% Compound 1 40 .mu.l of Compound 1 + 1960
.mu.l of 1000 .mu.l of 2% Comp1 + 1000 .mu.l of 1000 .mu.l of 1%
Compl + 1000 .mu.l Media Media of Media Compound 2 40 .mu.l of
Compound 2 + 3920 .mu.l of 1000 .mu.l of 2% Comp2 + 1000 .mu.l of
1000 .mu.l of 1% Compl + 2000 .mu.l Media Media of Media Compound 3
40 .mu.l of Compound 3 + 3920 .mu.l of 1000 .mu.l of 2% Comp3 +
1000 .mu.l of 1000 .mu.l of 1% Comp3 + 1000 .mu.l Media Media of
Media Compound 4 40 .mu.l of Compound 4 + 3920 .mu.l of 1000 .mu.l
of 2% Comp4 + 1000 .mu.l of 1000 .mu.l of 1% Comp4 + 1000 .mu.l
Media Media of Media Compound 5 40 .mu.l of Compound 5 + 3920 .mu.l
of 1000 .mu.l of 2% Comp5 + 1000 .mu.l of 1000 .mu.l of 1% Comp5 +
1000 .mu.l Media Media of Media Compound 6 40 .mu.l of Compound 6 +
3920 .mu.l of 1000 .mu.l of 2% Comp6 + 1000 .mu.l of 1000 .mu.l of
1% Comp6 + 1000 .mu.l Media Media of Media Compound 7 40 .mu.l of
Compound 7 + 3920 .mu.l of 1000 .mu.l of 2% Comp7 + 1000 .mu.l of
1000 .mu.l of 1% Comp7 + 1000 .mu.l Media Media of Media Compound 8
40 .mu.l of Compound 8 + 3920 .mu.l of 1000 .mu.l of 2% Comp8 +
1000 .mu.l of 1000 .mu.l of 1% Comp8 + 1000 .mu.l Media Media of
Media Compound 9 40 .mu.l of Compound 9 + 3920 .mu.l of 1000 .mu.l
of 2% Comp9 + 1000 .mu.l of 1000 .mu.l of 1% Comp9 + 1000 .mu.l
Media Media of Media Compound 40 .mu.l of Compound 10 + 3920 .mu.l
of 1000 .mu.l of 2% Comp10 + 1000 .mu.l 1000 .mu.l of 1% Comp10 +
1000 .mu.l 10 Media of Media of Media DMSO 40 .mu.l of DMSO + 3920
.mu.l of Media 1000 .mu.l of 2% DMSO + 1000 .mu.l of 1000 .mu.l of
1% DMSO + 1000 .mu.l Media of Media
Example 10: General Assay Procedure for Determination of Caspase-3
Activity on HepG2 Cells
[0148] Cells that are suspected or have been induced to undergo
apoptosis are first lysed to collect their intracellular contents.
In our test system, lysates from cells treated with staurosporin
were tested for protease activity by the addition of a
caspase-specific peptide that is conjugated to the fluorescent
reporter molecule 7-amino-4-methyl coumarin (AMC). The cleavage of
the peptide by the caspase releases a fluorochrome that, when
excited at 380 nm wavelength, emits fluorescence at 460 nm. The
level of caspase enzymatic activity in the cell lysate is directly
proportional to the fluorescence signal detected with a fluorescent
microplate reader. Confluent HepG2 cells (70-80%) grown in T-75
flasks were detached using trypsin-EDTA. Following centrifugation,
the cells pellet was resuspended in DMEM medium and counted using a
hemocytometer. Cells were seeded into 96 well Plate at a density of
40,000 cells/100 .mu.l/well and incubated at 37.degree. C./5%
CO.sub.2 for 8 hrs. Media was removed and test compounds were added
in the volume of 100 .mu.L. After 30 min of pre treatment as above,
50 .mu.L of 3.times. conc. of Staurosporine (final concentration of
20 .mu.M) or 50 lut of medium (untreated control) was added to
respective wells. After inducing with Staurosporine for 16 h. cells
were lysed by addition of 50 .mu.l of lysis buffer followed by 30
min incubation. After complete lysis as observed under microscope
100 .mu.l of chilled buffer (assay buffer) was added to each well.
Next DEVD-AMC (substrate, final Conc. 15 uM) was added and allowed
the reaction to continue for 2 hrs. The fluorescence was measured
by exciting at 380 nM and capturing the emission at 460 nM using
BMG Polarstar fluorescent micro plate reader.
Example 11: Data Analysis of Example 10 Assays
[0149] Average the replicate Relative Fluorescence Value (RFU) for
each standards, blanks and samples. Enzyme activity of control
(staurosporine treated without inhibitor) was considered as 100%
activity (0% inhibition). Fluorescence values (RFU) of
Test/Reference compounds are compared against this for calculating
% inhibition. The percentage inhibition of Test/Reference compound
was calculated as follows:
% Activity = 100 .times. RFU of Test / Reference compound RFU of
Control ##EQU00002## % Inhibition = 100 - % Activity
##EQU00002.2##
IC.sub.50 values were determined by nonlinear regression analysis
(curve fit) of percent viability data against drug concentration
using the sigmoidal dose-response (variable) equation (Graph Pad
Prism 4 software). BCP-6 and BCP-7 demonstrated particular effect
on caspase-3 inhibition. Quality Control: The assay was evaluated
for following quality checks: [0150] (i) IC.sub.50 Value of
Reference Compound: IC.sub.50 value of Ac-DEVD-CHO [0151] (ii) %
Coefficient of Variance between Replicates: The % CV between
replicates was within the acceptable limits (10%).
Example 12: Extract of Lycopodium Clavatum Induces Morpholigcal
Features Consistent with Apoptosis
[0152] HeLa cells (cervical carcinoma) obtained from American Type
Tissue Culture (ATCC) were treated for 48 hours with the the
extract from Lycopodium Clavatum and stained with anti-tubulin
antibody to examine the cytoskeleton and nuclei were stained with
4',6-diamidino-2-phenylindole is a fluorescent stain that binds
strongly to DNA (DAPI). Cells treated with vehicle revealed intact
cytoplasmic structure and nuclei. While cells treated with the
extract lost their cytoplasmic structure (rounded cells) and
complete loss of nuclear DNA in cells as evidenced by loss of DNA
appearing as empty space in nuclei. These morphological changes
suggest that the BCP-21 induces apoptosis in cervical carcinoma
cell line.
Example 13: Extract of Lycopodium Clavatum Induces Sub-G1
Population
[0153] Since the extract of Lycopodium Clavatum induces changes
suggestive of apoptosis, apoptosis was evaluated by measuring DNA
content using flow cytomery. The apoptotic cells loss DNA by
fragmentation, hence would have DNA content less than 2n. On flow
cytometry analysis, the cells would appear to run left of G1 peak
and hence called `sub-G1 peak`. HeLa cells treated with control and
various dilutions (1:500) and 1:250 of the Lycopodium Clavatum
extract were fixed in absolute ethanol and stained with propidium
iodide for 30 mins with RNAse. The cells were analyzed at the core
facility of Dana Farber Cancer Institute, Harvard Medical School
(Boston, Mass.). MultiCycle software from Phoenix Flow Systems (San
Diego, Calif.) will be used to deconvolute the cellular DNA content
histograms to obtain quantitation of the percentage of cells in
sub-G1 phase.
[0154] The crude extract of Lycopodium Clavatum increased sub-G1
peak (23%) compared to the control (6.7%) in a dose dependent
manner (FIG. 6). The data strongly indicate that the extract
induces apoptosis of HeLa cells in a dose-dependent manner.
Example 14: Extract of Lycopodium Clavatum Induces PARP
Cleavage
[0155] Cells were lysed in 50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 30
mM EDTA, 0.5% Triton X-100 with complete protease inhibitor
(Roche). Protein samples were separated on an appropriate
percentage of gel by SDS-PAGE. In general, 20-60 jig of protein
were analyzed for endogenous proteins and 10-15 .mu.g for
transfected proteins. Protein was transferred to 0.2 .mu.m
nitrocellulose membrane (Bio-Rad) for 1 h at 4.degree. C. for 1 h.
Membranes were blocked for 45 minutes at room temperature (RT) in
PBS solution containing 5% milk and 0.1% Tween-20 (American
Bioanalytical. The nitrocellulose membrane was then incubated in
primary antibody diluted at an appropriate concentration in PBS
containing 1% milk and 0.1% Tween-20 for either 2 h at RT or
overnight 4.degree. C. Upon removal of the primary antibody, the
membranes were washed 3 times for 10 minutes at RT in wash buffer
(1.times.PBS with 1% milk and 0.1% Tween-20). The membrane was then
incubated for 1 h at RT in the appropriate secondary antibody
diluted in wash buffer. Membrane was then washed for 3 times for 10
minutes. Western blot were developed using ECL (Pierce
Laboratories) according to the manufacturer's instructions.
[0156] The result indicates that full length PARP (mol. wt. 116
kDa) was completely cleaved after 24 hours. HeLa cells treated with
the extract show increase in PARP cleavage in a time-dependent
manner (FIG. 7). This data strongly indicate that the Lycopodium
extract induces apoptosis.
Example 15: Screening of Racemic Mixture of 8-HHA Against Human
Tumor Cell Lines
[0157] The synthesized racemic mixture of 8-HHA dissolved in DMSO
was accepted by the Division of Cancer Diagnosis and Treatment,
National Cancer Institute, NIH for screening against 60 human tumor
cell line panel. The screening is a microplate cytotoxicity assays
based on a simple colorimetric (MTT) assay which relies on the
metabolic reduction of a tetrazolium dye in viable cells to a
colored formazan product. A modified protocol was used for the
screening of the compound and measures the inhibition of growth of
various tumor cell lines. The 8-HHA tested in this assay was at the
concentration of 10 .mu.M.
[0158] The result shows that 8-HHA has significantly suppressed the
growth of leukemia cell lines (e.g., CCRF-CEM, K-562, SR, MOLT-4,
RPMI-8226, and HL-60(TB)) ranging from 40-96%. It also demonstrated
a remarkable inhibition of growth on non-small cell lung cancer
cell lines (e.g, HOP-92, and NCI-H460). Also, three (i.e., HCT-116,
HCT-15, and KM12) out of 7 colorectal cancer cell lines screened
showed moderate evidence of growth suppression. This data indicates
that 8-HHA has growth inhibitory activity against various cancer
cell lines such as leukemia, lung and colorectal cancer cell lines,
albeit to a variable extent.
Example 16: The Effects of 8-HHA on Survival of Cancer Cell
Lines
1) Against the Lung Cancer Cell Lines:
[0159] The effect of the racemic mixture of 8-HHA and that of the
individual enantiomers, namely S and R enatiomers, were examined on
the survival of HOP-92 lung cancer cell lines. The cell viability
was examined in the exponential growth phase with 100 .mu.M of
8-HHA for 72 hours using colorimetric MTT assay. In separate
assays, HOP-92 cells were treated with different concentrations of
the S-enatiomer of 8-HHA ranging from 20-100 .mu.M for 72
hours.
[0160] The results show that the racemic mixture of 8-HHA reduced
the survival of HOP92 cell lines by 25%. The R-enantiomer reduced
the survival of HOP92 cell lines by 13%. In contrast, the
S-enatiomer had maximum effect on the survival of lung cancer cell
line (reduced by 72%). This data indicate that S enantiomer of
8-HHA has a potent inhibitory effect on HOP92 lung cancer cell
survival. Moreover, FIG. 8 shows that increasing concentrations of
(S)-8-HHA inhibited lung cancer cell line survival in a dose
dependent manner. A 50% reduction in cell survival (IC.sub.50) was
observed at approximately 90 .mu.M dose of S-enatiomer of 8-HHA.
This data strongly indicate that S enantiomer of 8-HHA has a
dose-dependent inhibitory effect on lung cancer cell line.
2) Against the Liver Cancer Cell Lines:
[0161] The effect of the racemic mixture of 8-HHA and that of the
individual enantiomers, namely S and R enatiomers, were examined on
survival of PLC/PRF/5 (also referred to as "PLC-5" or "PLCS"),
Hep3B and SNU449 (also referred to as "SNU") liver cancer cell
lines. The cell viability was examined in the exponential growth
phase with 100 .mu.M of 8-HHA for 72 hours using colorimetric MTT
assay. In separate assays, PLC-5 cells were treated with different
concentrations of S-enatiomer of 8-HHA ranging from 20-100 .mu.M
for 72 hours.
[0162] The results (FIG. 9) show that the racemic mixture of 8-HHA
reduced the survival of PLC-5 and Hep3B cell lines by 52-25%,
respectively. It had no major effect on SNU cell line. On the other
hand, the S-enatiomer of 8-HHA had the maximum effect on the
survival of all liver cancer cell lines (reduction of almost 75%
cell survival) compared to either the racemic mixture or
R-enatiomer. This data indicate that the S enantiomer of 8-HHA has
a potent inhibitory effect on all of the liver cancer cell
survival.
[0163] Further, FIG. 10 demonstrates that increasing concentrations
of (S)-8-HHA inhibited PLC-5 liver cancer cell line survival in a
dose dependent manner. A 50% reduction in cell survival (IC.sub.50)
was observed at approximately 50 .mu.M dose of S-enatiomer of 8-HHA
This data strongly indicate that S enantiomer of 8-HHA has a
dose-dependent inhibitory effect on lung cancer cell line.
Example 17: 8-HHA Induces Apoptosis in Liver and Lung Cancer Cell
Lines
[0164] PARP cleavage is considered a specific and well established
marker of apoptosis. During apoptosis, FAS receptor undergoes down
regulation, which is considered as an established indicator of
apoptosis. Apoptosis can be induced by a pathway stimulated by FAS
receptor binding to FAS ligand and is called extrinsic mechanism.
Apoptosis by this pathway results in the reduction of FAS receptor.
Therefore, a reduction in the protein levels of FAS receptor
indicates that the apoptosis is induced by the extrinsic
mechanism.
1) Against Liver Cancer Cell Lines:
[0165] Th effect of 8-HHA was examined on apoptosis in liver cancer
cell lines. FIG. 11 shows that the treatment of 100 .mu.M of the
S-enantiomer of 8-HHA resulted in the PARP cleavage in SNU and
PLC-5 liver cancer cell lines. This data indicate that 8-HHA
induces apoptosis in liver cancer cell line.
[0166] PLC-5 cell lines were treated with 100 8-HHA of 100 .mu.M
for 72 hours. This resulted in a substantial reduction in FAS
receptor levels with the treatment of (S)-8-HHA compared to the
control (FIG. 12). This data suggests that (S)-8-HHA induces
apoptosis in liver cancer cell line by the extrinsic pathway.
2) Against Lung Cancer Cell Lines:
[0167] HOP-92 lung cancer cell lines were treated with 100 .mu.M of
(S)-8-HHA for 72 hours. The (S)-8-HHA treatment resulted in the
reduction of FAS protein levels in HOP92 cell lines. This data
indicates that 8-HHA induces apoptosis in HOP92 cell lines through
extrinsic mechanism.
Example 18: The Effect of 8-HHA Treatment on Pro-Apoptotic Bim1 in
Lung Cancer Cell Line
[0168] Bim1 is a pro-apoptotic protein whose up regulation leads to
apoptosis. HOP92 cell lines were treated with 100 .mu.M of
S-enatiomer of 8-HHA for 72 hours. The results show that Bim1
increased by 2 fold in 8-HHA treated compared to the control
sample. This data indicate that 8-HHA induces apoptosis in lung
cancer cell lines.
Example 19: Determination of Maximal Tolerated Dose (MTD) of 8-HHA
for an In Vivo Animal Model
[0169] The purpose of this study was to determine the maximum
tolerated dose of 8-HHA following intravenous (IV) administration
in ICR mice. A racemic mixture of 8-HHA, placebo, and vehicle were
administered to 20 ICR female mice with weight of 25-30 grams,
respectively. The 8-HHA was formulated in nanolipid at
concentration of 0, 10, 20 and 40 mg/ml. There were 4 animals per
group and they were injected with 0, 10, 20 and 40 mg/kg dose of
8-HHA Mice were given a single bolus dose via the tail vein
according to group assignment. One week after dosing mice were
sacrificed. Daily clinical observations were performed 15 minutes
and 1 hour post dose. The mice were observed daily for any adverse
effects until necropsy on study day 8. Body weights were recorded
for all the mice prior to test substance administration, and every
other day throughout the test period. This entire study was
performed at Toxikon Corporation, Bedford, Mass. The results are
depicted in Table 6.
TABLE-US-00006 TABLE 6 Test Articles Dose Placebo 8-HHA Concen-
Volume Number of Group (mg/kg) (mg/kg) tration Route (mL/kg)
animals 1 0 0 0 IV 2 4 per group 2 0 10 5 3 0 20 10 4 0 40 20
Results and Discussions:
[0170] Body weight at day 6 and 8 did not vary from pre dose
weight. Body weight at day 6 and 8 did not vary from pre dose
weight. Two mice dosed with the high dose (40 mg/kg) died shortly
after being dosed. Animals dosed with placebo, 10 mg/kg and 20
mg/kg tolerated the 8 HHA well and did not demonstrate any clinical
abnormalities to be noted. The dose of 20 mg/kg was then considered
as maximum tolerated dose of 8-HHA
Example 20: Liver Xenograft Mouse Model
[0171] The purpose of this study was to determine anti tumor
efficacy of 8-HHA in liver cancer using PLCS cells a Hepatocellular
Carcinoma cell line. The tumor growth and animal survival were
considered as primary end point.
Animals and Care:
[0172] Thirty BABL/c nude, non-pregnant and nulliparous female mice
that are 5-6 weeks old and weighing 16-20 gms were used in this
study. BALB/c nu/nu mice were used because they have been
historically used in xenograft studies to test anti-tumor efficacy
of drug candidates. Mice were acclimatized for minimum 5 days,
under same conditions as for the actual test. Mice were housed at
room temperature 68.+-.5.degree. F. with room Relative Humidity of
30-70%, air Exchanges per Hour of a minimum of 10 changes per hour,
lights exposure of 12-hour light/dark cycle, full spectrum
fluorescent lights. The mice were housed in groups in ventilated
micro-isolator cages made up of polycarbonate. The mice were using
autoclaved laboratory grade bedding and were provided ad libitum
with irradiated pellets and autoclaved water. There were no known
contaminants present in the feed, water, or bedding expected to
interfere with the test data. The laboratory and animal rooms were
maintained as limited-access facilities.
Route of Injection and Dose:
[0173] 8-HHA was administered through intraperitoneal (IP)
injection. 8-HHA is poorly water soluble, hence suspended in
nanolipid dispersion solution (ePharse, Basel, Switerzland) at the
concentration of 27.2 mg/ml corresponding to 100 mM. The MTD assay
(Preliminary data) showed that the mice tolerated a maximum dose of
20 mg/kg. For this study, 2 doses-10 mg/kg and 100 mg/kg were
used.
Animal Preparation
Tumor Induction:
[0174] The cell line PLC5 were cultured according to recommended
specifications at Vanas Oncology, in which cells were grown and
maintained in RPMI medium containing 10% fetal bovine serum, 2 mM
L-Glutamine, 100 units/ml of Streptomycin and 100 units/ml of
Penicilin. Cells were trypizinized and counted using the
Trypan-blue viability test using a hemocytometer. Cell counts in
quadrants of the hemocytometer were converted to a cells/mL value,
which will enable isolation of the appropriate number of cells per
mouse. Each mouse was inoculated subcutaneously in the right flank
region with 0.2 mL of a 50% RPMI/50% Matrigel.TM. mixture
containing a suspension of tumor cells (5.times.10.sup.6
cells/mouse). Tumors were observed twice weekly until well
established. Tumor volume was calculated using the formula: Tumor
weight (mg)=(a.times.b.sup.2/2) where `b` is the smallest diameter
and `a` is the largest diameter in millimeters.
Allocation of Animals:
[0175] Once the established tumors reach a mean calculated volume
of approximately 50-100 mg, the mice were randomized, using
appropriate software, into treatment groups in order to reduce the
variability of tumor sizes per group.
Pre Dose Procedure:
[0176] Acclimated animals were weighed and observed for clinical
signs of toxicity prior to dosing on Day 1.
Dose Administration:
[0177] Two doses 1 and 10 mg/kg were administered based on the MTD
assay guideline. The first day of dosing is Day 1. On Day 1, 8-HHA,
and vehicle injections were administered according to the study
design in Table 7 below.
TABLE-US-00007 TABLE 7 Study Design Number of Duration of Model
Groups Animals Treatment Route Dosage Treatment Hepatocellular C1
10 Control IP NA Five days a week carcinoma model T1 10 8-HH A 10
for 3 mg/kg weeks T2 10 8-HHA 100 mg/kg
Post-Dose Procedure:
[0178] Following treatment. tumor and mouse body weight
measurements were recorded twice weekly and gross observation was
made at least once daily. Mice with tumors that are not palpable
was considered complete regressions. Percentage of mice mortality
and time of death will be recorded for every group in the study.
Animals may be defined as moribund and sacrificed if one or more of
the following criteria are met: [0179] Loss of body weight of 20%
or greater in a 1 week period. [0180] Mice that inhibit normal
physiological function such as eating, drinking, mobility, and
ability to urinate and/or defecate. [0181] Tumors that exceed a
maximum size of 2000 mg as measured by calipers. [0182] Ulcerated
tumors, or tumors that bleed or produce exudates. [0183] Prolonged,
excessive diarrhea leading to excessive weight loss (>20%).
[0184] Persistent wheezing and respiratory distress. [0185]
Prolonged or excessive pain or distress as defined by clinical
observations such as: prostration, hunched posture,
paralysis/paresis, distended abdomen, ulcerations, abscesses,
seizures, and/or hemorrhages.
[0186] After completion of dosing, mice were observed for
additional two weeks to check for regrowth of tumors.
Sacrifice:
[0187] All animals will be sacrificed at the termination of the
study, and the tumor will be harvested. One portion of the tumor
will be frozen in OCT solution and the other portion will be fixed
in formalin. The frozen and fixed tissues will be sent to the
Sponsor.
[0188] All the animal experiments were performed at Toxikon
Corporation (Bedford, Mass.).
Results:
[0189] On day 1 of 8-HHA treatment, mice were randomly divided into
three groups with 10 mice per group: control group vehicle only
(C1), 8-HHA 10 mg/Kg body weight (T1) and 100 mg/Kg body weight
(T2). Both the group T1 and T2 significantly inhibited tumor growth
in mice from day 4 of 8-HHA treatment. In contrast, in the 8-HHA
treated group (T1), the tumor volumes were decreased by 44.5%,
49.8%, 72.3%, 77.7% and 78.4% 9 (on days 4, 9, 11, 16 and 18,
respectively) compared to the control group. In the T2 group, the
tumor volumes were decreased by 56.3%, 61.1%, 81.1%, 87.9% and
88.3% (on days 4, 9, 11, 16 and 18, respectively) (see FIG. 13 and
Table 8).
[0190] These results show that the two concentrations of 8-HHA used
in this study decreases tumor growth in the liver cancer mouse
model, by anti-proliferative and pro-apoptotic effects as evidenced
from our in vitro experiments using PLC-5 cells. 8-HHA may thus
prove to be a very effective, safe, and inexpensive adjunct to
standard chemotherapy regimens.
(*S: Significant compared to control group; N=10/group)
Mean.+-.SEM Tumor Volume (PLC-5)
TABLE-US-00008 [0191] TABLE 8 Randomization Groups (Pre-Dose) Day 2
Day 4 Day 9 Day 11 Day 16 Day 18 Control 53.81 .+-. 7.90 88.57 .+-.
10.52 95.40 .+-. 12.06 93.71 .+-. 11.19 148.3 .+-. 27.75 165.3 .+-.
28.92 164.6 .+-. 25.02 BCP-21 56.73 .+-. 16.11 76.17 .+-. 12.01
66.21 .+-. 11.71 61.85 .+-. 10.29* 61.89 .+-. 10.97* 54.46 .+-.
12.65* 51.91 .+-. 12.42* 10 mg/kg BCP-21 53.42 .+-. 9.56 71.42 .+-.
8.10 52.91 .+-. 6.7* 47.97 .+-. 9.59* 42.22 .+-. 8.25* 29.52 .+-.
9.30* 26.69 .+-. 9.39* 100 mg/kg Statistical NS NS *S *S *S *S *S
Significance P > 0.05 P > 0.05 P < 0.05 P < 0.05 P <
0.05 P < 0.05 P < 0.05
Example 21: Small Cell Lung Cancer Xenograft Mouse Model
[0192] The purpose of this study was to determine anti tumor
efficacy of 8-HHA in lung cancer using HOP92 cells.
Animals and Care:
[0193] Thirty BABL/c nude, non-pregnant and nulliparous female mice
that are 5-6 weeks old and weighing 16-20 gms were used in this
study. BALB/c nu/nu mice were used because they have been
historically used in xenograft studies to test anti-tumor efficacy
of drug candidates. Mice were acclimatized for minimum 5 days,
under same conditions as for the actual test. Mice were housed at
room temperature 68.+-.5.degree. F. with room Relative Humidity of
30-70%, air Exchanges per Hour of a minimum of 10 changes per hour,
lights exposure of 12-hour light/dark cycle, full spectrum
fluorescent lights. The mice were housed in groups in ventilated
micro-isolator cages made up of polycarbonate. The mice were using
autoclaved laboratory grade bedding and were provided ad libitum
with irradiated pellets and autoclaved water. There were no known
contaminants present in the feed, water, or bedding expected to
interfere with the test data. The laboratory and animal rooms were
maintained as limited-access facilities.
Route of Injection and Dose:
[0194] 8-HHA was administered through intraperitoneal (IP)
injection. 8-HHA is poorly water soluble, hence suspended in
nanolipid dispersion solution (ePharse, Basel, Switerzland) at the
concentration of 27.2 mg/ml corresponding to 100 mM. The MTD assay
(Preliminary data) showed that the mice tolerated a maximum dose of
20 mg/kg.
EXPERIMENTAL DESIGN
Animal Preparation
Tumor Induction:
[0195] The cell line HOP92 were cultured according to recommended
specifications at Vanas Oncology as above discussed in Example 20.
Cells were trypizinized and counted using the Trypan-blue viability
test using a hemocytometer. Cell counts in quadrants of the
hemocytometer were converted to a cells/mL value, which will enable
isolation of the appropriate number of cells per mouse. Each mouse
was inoculated subcutaneously in the right flank region with 0.2 mL
of a 50% RPMI/50% Matrigel.TM. mixture containing a suspension of
tumor cells (5.times.10.sup.6 cells/mouse). Tumors were observed
twice weekly until well established. Tumor volume was calculated
using the formula: Tumor weight (mg)=(a.times.b.sup.2/2) where `b`
is the smallest diameter and `a` is the largest diameter in
millimeters.
Allocation of Animals:
[0196] Once the established tumors reach a mean calculated volume
of approximately 50-100 mg, the mice were randomized, using
appropriate software, into treatment groups in order to reduce the
variability of tumor sizes per group.
Pre Dose Procedure:
[0197] Acclimated animals were weighed and observed for clinical
signs of toxicity prior to dosing on Day 1.
Dose Administration:
[0198] Two doses 1 and 10 mg/kg were administered. The first day of
dosing is Day 1. On Day 1, 8-HHA, and vehicle injections are
administered according to the study design in Table 9 below.
TABLE-US-00009 TABLE 9 Study Design Number of Duration of Model
Groups Animals Treatment Route Dosage Treatment Non-Small cell Cl
10 Control IP NA Five days a week lung cancer T1 10 8-HHA 10 mg/kg
for 3 weeks T2 10 8-HHA 100 mg/kg
Post Dose Procedure:
[0199] Following treatment, tumor and mouse body weight
measurements were recorded twice weekly and gross observation was
made at least once daily. Mice with tumors that were not palpable
was considered complete regressions. Percentage of mice mortality
and time of death were recorded for every group in the study.
Animals may be defined as moribund and sacrificed if one or more of
the following criteria are met: [0200] Loss of body weight of 20%
or greater in a 1 week period. [0201] Mice that inhibit normal
physiological function such as eating, drinking, mobility, and
ability to urinate and/or defecate. [0202] Tumors that exceed a
maximum size of 2000 mg as measured by calipers. [0203] Ulcerated
tumors, or tumors that bleed or produce exudates. [0204] Prolonged,
excessive diarrhea leading to excessive weight loss (>20%).
[0205] Persistent wheezing and respiratory distress. [0206]
Prolonged or excessive pain or distress as defined by clinical
observations such as: prostration, hunched posture,
paralysis/paresis, distended abdomen, ulcerations, abscesses,
seizures, and/or hemorrhages.
[0207] After completion of dosing, mice were observed for
additional two weeks to check for regrowth of tumors.
Sacrifice:
[0208] All animals will be sacrificed at the termination of the
study, and the tumor will be harvested. One portion of the tumor
will be frozen in OCT solution and the other portion will be fixed
in formalin. The frozen and fixed tissues were sent to the
Sponsor.
Results:
[0209] On day 1 of 8-HHA treatment, mice were randomly divided into
three groups with 10 mice per group: control group vehicle only
(C1), 8-HHA 10 mg/Kg body weight (T1) and 100 mg/Kg body weight
(T2). Both the group T1 and T2 significantly inhibited tumor growth
in mice from day 16 of 8-HHA treatment. The tumor volumes were
214.6.+-.38.65, and 258.4..+-.64.96 mm.sup.3 on days 16 and 18,
respectively, in the control group. In contrast, in the 8-HHA
treated group (T1), the tumor volumes were 88.78.+-.28.61 and
82.02.+-.25.93 mm.sup.3 on days 16 and 18, respectively,
corresponding to 58.6%, and 68.2% decreases in tumor 32.63 mm.sup.3
on days 16 and 18, respectively, corresponding to 56.5%, and 73.1%
decreases in tumor volume (see Table 10 and FIG. 14)
TABLE-US-00010 TABLE 10 Randomization Groups (Pre-Dose) Day 2 Day 4
Day 9 Day 11 Day 16 Day 18 Control 87.18 .+-. 28.73 120.7 .+-.
30.09 169.4 .+-. 56.48 174.6 .+-. 35.93 189.1 .+-. 34.53 214.6 .+-.
38.65 258.4 .+-. 64.96 BCP-21 89.64 .+-. 30.12 128.9 .+-. 32.45
116.0 .+-. 39.22 99.92 .+-. 32.57 94.31 .+-. 30.19 88.78 .+-.
28.61* 82.08 .+-. 25.93* 10 mg/kg BCP-21 86.68 .+-. 14.32 141.6
.+-. 31.42 120.7 .+-. 26.45 106.1 .+-. 25.47 105.3 .+-. 29.05 93.38
.+-. 30.46* 91.27 .+-. 32.63* 100 mg/kg Statistical NS NS NS NS NS
*S *S Significance P > 0.05 P > 0.05 P > 0.05 P > 0.05
P > 0.05 P < 0.05 P < 0.05 *S: Significant compared to
control group Mean .+-. SEM Tumor Volume (HOP-92) (N =
10/group)
[0210] In conclusion, the two concentrations of 8-HHA used in this
study decreased tumor growth in the lung cancer mouse model, by
anti-proliferative and pro-apoptotic effects as evidenced from our
in vitro experiments using HOP92 cells. 8-HHA may thus prove to be
a very effective, safe, and inexpensive adjunct to standard
chemotherapy regimens.
[0211] Although the invention has been disclosed with reference to
specific embodiments, it is apparent that other embodiments and
variations of the invention may be devised by others skilled in the
art without departing from the true spirit and scope of the
invention.
* * * * *